

Cite this: DOI: 10.1039/c0dt01595d

www.rsc.org/dalton

PERSPECTIVE

A practical guide to the construction of radiometallated bioconjugates for positron emission tomography

Brian M. Zeglis and Jason S. Lewis*

Received 16th November 2010, Accepted 7th February 2011

DOI: 10.1039/c0dt01595d

Positron emission tomography (PET) has become a vital imaging modality in the diagnosis and treatment of disease, most notably cancer. A wide array of small molecule PET radiotracers have been developed that employ the short half-life radionuclides ^{11}C , ^{13}N , ^{15}O , and ^{18}F . However, PET radiopharmaceuticals based on biomolecular targeting vectors have been the subject of dramatically increased research in both the laboratory and the clinic. Typically based on antibodies, oligopeptides, or oligonucleotides, these tracers have longer biological half-lives than their small molecule counterparts and thus require labeling with radionuclides with longer, complementary radioactive half-lives, such as the metallic isotopes ^{64}Cu , ^{68}Ga , ^{86}Y , and ^{89}Zr . Each bioconjugate radiopharmaceutical has four component parts: biomolecular vector, radiometal, chelator, and covalent link between chelator and biomolecule. With the exception of the radiometal, a tremendous variety of choices exists for each of these pieces, and a plethora of different chelation, conjugation, and radiometallation strategies have been utilized to create agents ranging from ^{68}Ga -labeled pentapeptides to ^{89}Zr -labeled monoclonal antibodies. Herein, the authors present a practical guide to the construction of radiometal-based PET bioconjugates, in which the design choices and synthetic details of a wide range of biomolecular tracers from the literature are collected in a single reference. In assembling this information, the authors hope both to illuminate the diverse methods employed in the synthesis of these agents and also to create a useful reference for molecular imaging researchers both experienced and new to the field.

Introduction

Over the course of the past fifty years, advances in medical imaging have revolutionized clinical practice, with a wide variety of imaging modalities playing critical roles in the diagnosis and treatment

Department of Radiology and Program in Molecular Pharmacology and Chemistry Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. E-mail: lewisj2@mskcc.org; Fax: (646)-888-3039; Tel: (646)-888-3038



Brian M. Zeglis, Ph.D.

Dr. Brian Zeglis received his B.S. in chemistry summa cum laude from Yale University (2004), where he worked under the guidance of Professor Robert H. Crabtree. For his graduate studies, he attended the California Institute of Technology as an NSF pre-doctoral fellow. At Caltech, Brian worked under the mentorship of Professor Jacqueline K. Barton, studying the synthesis and development of DNA-binding octahedral metal complexes. After receiving his Ph.D. (2009), Brian moved to Memorial Sloan-Kettering Cancer Center, where he works as an NIH post-doctoral fellow in the laboratory of Professor Jason S. Lewis. Currently, his research is focused on the design, synthesis, and evaluation of ^{64}Cu - and ^{89}Zr -based PET radiopharmaceuticals.



Jason S. Lewis, Ph.D.

Professor Lewis earned a B.Sc. Hons (1992) and an M.Sc. (1993) in Chemistry from the University of Essex. He received a Ph.D. in Biochemistry (1996) from the University of Kent at Canterbury. Following his post-doctoral study at the Washington University School of Medicine, he joined the Radiology faculty (2003). In 2008, he moved to Memorial Sloan-Kettering Cancer Center (New York) where he is currently a Member (with tenure) and Vice Chairman for Basic Research, Chief Attending Radiochemist, and Director of the Cyclotron Core. He holds joint appointments at the Sloan-Kettering Institute, Weill Cornell Medical College and Gerstner Sloan-Kettering Graduate School. Professor Lewis has co-authored over 110 peer-reviewed journal articles, reviews and book chapters.

of disease. Today, clinicians have at their disposal a remarkable range of medical imaging techniques, from more conventional modalities like ultrasound, conventional radiography (X-rays), X-ray computed tomography (CT scans), and magnetic resonance imaging (MRI) to more specialized methodologies such as single-photon emission computed tomography (SPECT) and positron emission tomography (PET).

In recent years, medical imaging research has experienced a paradigm shift from its foundations in anatomical imaging towards techniques aimed at probing tissue phenotype and function.¹ Indeed, both the cellular expression of disease biomarkers and fluctuations in tissue metabolism and microenvironment have emerged as extremely promising targets for imaging.² Without question, the unique properties of radiopharmaceuticals have given nuclear imaging a leading role in this movement. The remarkable sensitivity of PET and SPECT combines with their ability to provide information complementary to the anatomical images produced by other modalities to make these techniques ideal for imaging biomarker- and microenvironment-targeted tracers.^{3,4} Both relatively young modalities, SPECT and PET have had an impact on medicine (and oncology in particular), which belies their novelty, and both have been the topic of numerous thorough and well-reasoned reviews.⁵⁻⁹ Both modalities have become extremely important in the clinic, and while PET is generally more expensive on both the clinical and pre-clinical levels, it also undoubtedly possesses a number of significant advantages over its single-photon cousin, most notably the ability to quantify images, higher sensitivity (PET requires tracer concentrations of $\sim 10^{-8}$ to 10^{-10} M, while SPECT requires concentrations approaching 10^{-6} M), and higher resolution (typically 6–8 mm for SPECT, compared to 2–3 mm or lower for PET). Therefore, in the interest of scope, the article at hand will limit itself to the younger and higher resolution of the techniques: positron emission tomography.

Regardless of the broader perspective, any discussion of PET benefits from a brief description of the underlying physical phenomena. Starting from the beginning, a positron released by a decaying radionuclide will travel in a tissue until it has exhausted its kinetic energy. At this point, it will encounter its antiparticle, an electron, and the two will mutually annihilate, completely

converting their mass into two 511 keV γ -rays that must, due to conservation of momentum, have equal energies and travel 180° relative to one another. These γ -rays will then leave the tissue and strike waiting coincidence detectors; importantly, only when signals from two coincidence detectors simultaneously trigger the circuit is an output generated. The two principal advantages of PET thus lie in the physics: the short initial range of the positrons results in high resolution, and the coincidence detection methodology allows for tremendous sensitivity.

In the early 1950s, Brownell¹⁰ and Sweet¹¹ developed the first devices for creating images using the coincident detection of γ -rays emitted from positron-electron annihilation events. At the same time, these researchers and others were pioneering the oncologic applications of positron imaging, specifically the imaging of brain tumors.¹⁰⁻¹⁴ Not until the 1970s, however, did the field take the next important practical step forward: tomographic systems and computer analysis were first applied to positron imaging, innovations which paved the way for the widespread clinical use of the modality.

Since the advent of PET in both the clinic and medical research laboratories, a number of positron-emitting isotopes have been developed for use in radiopharmaceuticals. For years, the field was dominated by small molecule tracers, radiopharmaceuticals whose short biological half-lives favor the use of non-metallic radionuclides with correspondingly short radioactive half-lives, such as ^{18}F , ^{15}O , ^{13}N , and ^{11}C (Table 1). In many ways, this is still true: [^{18}F]-fluoride and the ubiquitous [^{18}F]-fluorodeoxyglucose ([^{18}F]-FDG) are the only FDA-approved PET radiopharmaceuticals commonly employed in oncology ([^{13}N]- NH_3 and [^{82}Rb]- RbCl are FDA-approved but are used principally for myocardial perfusion scans). Further still, an examination of the list of PET radiotracers currently in NIH-sponsored clinical trials reveals an overwhelming majority of agents with non-metallic radionuclides, including among others the promising agents [^{18}F]-FLT, [^{18}F]-FES, [^{18}F]-FDHT, [^{18}F]-FMISO, [^{18}F]-FACBC, [^{18}F]-fluoroethylcholine, [^{18}F]-deshydroxycholine, [^{18}F]-FMAU, [^{11}C]-acetate, [^{11}C]-choline, [^{11}C]-MeAIB, [^{11}C]-MET, [^{124}I]-IAZGP, and [^{124}I]-FIAU.¹⁵

Yet despite the significant successes of small molecule probes labeled with non-metallic isotopes, these radionuclides possess

Table 1 Physical decay characteristics of conventional PET radionuclides^{158,159}

Radionuclide	Half-life	Decay mode (% branching ratio)	Production route	E(β^+)/keV	β^+ end-point energy/keV	Abundance, I $_{\beta^+}$ /%	E $_{\gamma}$ /keV (intensity, I $_{\gamma}$ /%)
^{11}C	1223.1 (12) s	β^+ (100)	$^{14}\text{N}(p,a)^{11}\text{C}$	385.6 (4)	960.2 (9)	99.759 (15)	511.0 (199.5)
^{13}N	9.965 (4) m	β^+ (100)	$^{16}\text{O}(p,a)^{13}\text{N}$	491.82 (12)	1198.5 (3)	99.8036 (20)	511.0 (199.6)
^{15}O	122.24 (16) s	β^+ (100)	$^{15}\text{N}(p,n)^{15}\text{O}$ $^{14}\text{N}(d,n)^{15}\text{O}$	735.28 (23)	1732.0 (5)	99.9003 (10)	511.0 (199.8)
^{18}F	109.77 (5) m	β^+ (100)	$^{18}\text{O}(p,n)^{18}\text{F}$ $^{20}\text{Ne}(d,a)^{18}\text{F}$	249.8 (3)	633.5 (6)	96.73 (4)	511.0 (193.5)
^{124}I	4.1760 (3) d	$\epsilon + \beta^+$ (100) β^+ (22.7 [13])	$^{124}\text{Te}(p,n)^{124}\text{I}$	687.04 (85) 974.74 (85)	1,534.9 (19) 2,137.6 (19)	11.7 (10) 10.7 (9)	511.0 (45) 602.7 (62.9) 722.8 (10.4) 1,691.0 (11.2)

ϵ = electron capture; m = minutes; d = days; s = seconds. Where positrons or γ -rays of different energies are emitted, only those with abundances of greater than 10% are listed. Unless otherwise stated, standard deviations are given in parentheses.

a few critical limitations. First, the short half-lives of the most common non-metallic radionuclides - approximately 20 min for ^{11}C , 10 min for ^{13}N , 2 min for ^{15}O , and 110 min for ^{18}F - allow only for investigations of biological processes on the order of minutes or a few hours using tracers with rapid pharmacokinetic profiles. Second, both the short half-lives of the radionuclides and the frequent necessity of incorporating the radioisotopes into the core structure of the tracer (rather than in an appended chelator or prosthetic group) often necessitate demanding and complex syntheses. Third, the clinical and pre-clinical use of short half-life, non-metallic radionuclides often requires a local cyclotron facility; in its absence, the radionuclide in question will undergo many half-lives of decay while in transit. Given the resources required for the construction and operation of medical cyclotrons, this is simply not an option in many locations.

These limitations have been brought into focus by the increasing study and development of biomolecular targeting agents for cancer, including short peptides, antibodies, antibody fragments, and natural and non-natural oligonucleotides. Given that Nature herself has designed or inspired these agents, they often show sensitivities and specificities for cancer cell biomarkers that far exceed those of their small molecule counterparts. However, these biomolecular tracers typically have biological half-lives that are much longer than the radioactive half-lives of the most common non-metallic positron-emitting radionuclides; further, though less pressing, many of these biomolecules are incompatible with the chemistry required for direct labeling with non-metallic radionuclides.^{16–19}

Given the enormous potential of biomolecular imaging agents, significant effort has been dedicated to the production, purification, and radiochemistry of positron-emitting radioisotopes of the metals Zr, Y, Ga, and Cu. These isotopes, specifically ^{64}Cu , ^{68}Ga , ^{86}Y , and ^{89}Zr , have radioactive half-lives (roughly 12.7, 1.1, 14.7, and 78.4 h, respectively) that favorably complement the biological half-lives of many biomolecular targeting vectors (Table 2). Although all four radiometals emit positrons, each

has a characteristic positron range, which is the principal factor in determining imaging resolution. ^{64}Cu and ^{89}Zr emit very low energy positrons, producing image resolution comparable to that of ^{18}F . ^{86}Y and ^{68}Ga , in contrast, emit higher energy positrons, which can result in slightly lower imaging resolutions, though this can be corrected through the use of mathematical algorithms.²⁰ Further still, and equally critical, all four metals form stable chelate complexes that may be employed for the radiolabeling of biomacromolecules. To be sure, not all biomolecular PET tracers are labeled with radiometals, nor are all radiometallated PET tracers biomolecules. An ^{18}F -labeled variant of the integrin-targeting RGD peptide²¹ and an ^{124}I -labeled carbonic anhydrase-targeting antibody²² have produced very exciting results and are currently being employed in human studies. Moreover, a few radiometal-based small molecule tracers have also proved extremely promising, most notably [^{64}Cu]-Cu(PTSM)²³ and [^{64}Cu]-Cu(ATSM),²⁴ with the latter currently in a multi-center clinical trial as an imaging agent for hypoxia.^{25–28} Yet, despite these exceptions, the single most important application of positron-emitting radiometals is the development of tracers based on peptides, antibodies, and oligonucleotides.

Importantly, the basic strategy for the incorporation of a radiometal into a biomolecule differs somewhat from the synthesis of a small molecule radiotracer containing a non-metallic PET radionuclide. In small molecule tracers, the radionuclide most often replaces an isotopologue (e.g. [^{11}C]-acetate or [^{15}O]- H_2O) or is incorporated into the basic structure of a molecule with either the intent of strategically altering the behavior of the parent molecule (e.g. [^{18}F]-FDG) or, more likely, disturbing the activity of the parent molecule as little as possible (e.g. [^{18}F]-FDHT or [^{18}F]-FES). In contrast, in biomolecular tracers, the radiometal is almost never directly attached to the biomolecule itself. Rather, the radionuclide is bound to a chelating moiety (e.g. DOTA²⁹ or EDTA³⁰), which is first covalently appended to the biomolecule with the intent of altering the vector's biochemical properties as little as possible.^{31,32}

Table 2 Physical decay characteristics of common PET radiometals⁴⁰

Radionuclide	Half-life	Decay mode (% branching ratio)	Production route	E(β^+)/keV	β^+ end-point energy/keV	Abundance, I $_{\beta^+}$ /%	E $_{\gamma}$ /keV (intensity, I $_{\gamma}$ /%)	Ref.
^{64}Cu	12.701(2) h	$\varepsilon + \beta^+$ (61.5 [3]) β^+ (17.6 [22]) β^- (38.5 [3])	$^{64}\text{Ni}(p,n)^{64}\text{Cu}$	278.21 (9)	653.03 (20)	17.60 (22)	511.0 (35.2)	84, 85
^{68}Ga	67.71 (9) m	$\varepsilon + \beta^+$ (100) β^+ (89.14 [12])	$^{68}\text{Ge}/^{68}\text{Ga}$	836.02 (56)	1889.1 (12)	87.94 (12)	511.0 (178.3)	160, 70, 161
^{86}Y	14.74 (2) h	$\varepsilon + \beta^+$ (100) β^+ (31.9 [21])	$^{86}\text{Sr}(p,n)^{86}\text{Y}$	535 (7)	1221 (14)	11.9 (5)	443.1 (16.9) 511.0 (64) 627.7 (36.2) 703.3 (15) 777.4 (22.4) 1076.6 (82.5) 1153.0 (30.5) 1854.4 (17.2) 1920.7 (20.8)	77
^{89}Zr	78.4 (12) h	$\varepsilon + \beta^+$ (100) β^+ (22.74 [24])	$^{89}\text{Y}(p,n)^{89}\text{Zr}$	395.5 (11)	902 (3)	22.74 (24)	511.0 (45.5) 909.2 (99.0)	79, 83, 162–164

ε = electron capture; m = minutes; h = hours; s = seconds. Where positrons or γ -rays of different energies are emitted, only those with abundances of greater than 10% are listed. Unless otherwise stated, standard deviations are given in parentheses.

As new targets are described and radiometals become more available to the wider molecular imaging community, the amount of research into radiometal-based PET tracers has exploded in recent years. For example, over 60% of all publications describing ^{89}Zr -PET have been published in the last four years (with well over 20% in 2010 alone).³³ Indeed, the dramatic growth in this area and the expansion in the availability of radiometals have had the dual effects of broadening the appeal of biomolecular PET imaging and opening the field to investigators who previously may have left the development of PET probes to dedicated radiochemistry and molecular imaging laboratories. However, the frenetic pace of the field and the array of choices in chelation, conjugation, and metallation strategies may serve as an obstacle to those who are interested in the development of radiometallated PET tracers but lack significant bioconjugation or radiochemical experience.

This perspective aims at lowering this barrier. Here, we strive to create a practical guide to the synthesis of radiometal-based PET tracers. To this end, we have compiled the experimental details of chelator choice, conjugation strategy, and radiometallation conditions from the syntheses of a wide array of ^{64}Cu -, ^{68}Ga -, ^{86}Y -, and ^{89}Zr -labeled PET agents. Typically, reviews discuss the structure, behavior, biology, and imaging applications of these agents, with the experimental details touched upon only briefly or simply referenced.^{7,16,34–37} All too often, however, the search for a specific conjugation or metallation protocol results in an elongated, and in some cases circuitous, trek through the literature to find a simple incubation time or buffer concentration. Importantly, we do not strive for an exhaustive review of the radiochemistry or imaging applications of radiometal-based PET tracers. Others - most notably Carolyn Anderson and her coworkers at the Washington University School of Medicine and Martin Brechbiel and his coworkers at the National Cancer Institute - have produced well-written and remarkably thorough reviews on these topics.^{3,30,34,38–45}

The core of this perspective lies not in the text but rather in the series of tables containing the practical details of chelator conjugation and radiometallation from a diverse collection of ^{64}Cu -, ^{68}Ga -, ^{86}Y -, and ^{89}Zr -labeled bioconjugates. We have elected not to include two types of macromolecular radiopharmaceuticals, bispecific antibodies and biomolecule-based nanoparticles, in the interest of space and scope, though these have been addressed well elsewhere.^{46–49} Further, it is important to note that some of the conjugation strategies described herein are now, for the most part, obsolete with respect to their original vector; for example, a number of syntheses for DOTATOC will be outlined, though this DOTA-modified somatostatin analogue is now widely commercially available. Yet we believe it is important to detail these conjugation methods nonetheless, for the synthetic routes themselves may prove useful in the future for the creation of conjugates with different biomolecular vectors. In collecting these techniques in one place, we hope not only to shed light upon the diverse methods employed in the synthesis of these agents but also, and perhaps more importantly, to create a useful reference for both experienced molecular imaging scientists and researchers new to the field.

The anatomy of a PET bioconjugate

A radiometallated PET bioconjugate has four component parts, each of which must be carefully considered during the design and synthesis of the tracer: (1) the biomolecular targeting vector, (2)

the radiometal, (3) the chelator, and (4) the linker connecting the chelator and the biomolecule (Fig. 1). A detailed discussion of the possible targeting vectors lies outside the scope of this work, though biomolecules ranging from cyclic pentapeptides and short oligonucleotides to 40-amino acid peptides, antibody fragments, and full antibodies have been employed.³⁰ Of course, the most important facet of the biomolecule moiety is its specificity for its biomarker target. Indeed, a wide array of biomarkers have been exploited. Most often, the chosen target is a cell surface marker protein or receptor, such as the somatostatin receptor family (SSTR),⁵⁰ integrin family (*e.g.* $\alpha_v\beta_3$),⁵¹ gastrin-releasing peptide receptor (GRPR),⁵² and epidermal growth factor receptor (EGFR).⁵³ In more specialized cases, disialogangliosides (*e.g.* GD2), mRNA gene products, and even the low pH environment of tumors have been targeted by antibodies,⁵⁴ oligonucleotides,⁵⁵ and short peptides,⁵⁶ respectively. Targeting cytosolic proteins and enzymes with antibodies and oligopeptides is rare due to the considerable difficulty of getting large biomolecules into the cytoplasm. However, significant progress is being made in the development of cell- and nucleus-penetration strategies, and this technology may prove productive for intracellular or intranuclear PET imaging agents in the near future.




Fig. 1 The anatomy of a PET bioconjugate.

Radiometals: properties and production

The principal radiometals employed for the labeling of biomolecular tracers are ^{64}Cu , ^{68}Ga , ^{86}Y , and ^{89}Zr . Of course, these are not the only positron-emitting radiometals. Some metallic radioisotopes, such as ^{60}Cu , ^{61}Cu , ^{62}Cu , ^{82}Rb , $^{52\text{m}}\text{Mn}$, and $^{94\text{m}}\text{Tc}$, have been used in PET studies to varying degrees, but their half-lives make them far better suited for small molecule tracers (*e.g.* [^{60}Cu]-Cu(ATSM)).^{57–60} Other positron-emitting radiometals, including ^{45}Ti ([^{45}Ti]-transferrin⁶¹), ^{52}Fe ([^{52}Fe]-citrate/transferrin⁶²), ^{55}Co ([^{55}Co]-antiCEA F(ab')₂^{63,64}), ^{66}Ga ([^{66}Ga]-octreotate⁶⁵), $^{110\text{m}}\text{In}$ ([$^{110\text{m}}\text{In}$]-octreotate⁶⁶), and ^{74}As ([^{74}As]-bavituximab^{67,68}), have been employed in the synthesis of biomolecular radiopharmaceuticals.⁴¹ However, these will not receive more than a brief discussion here, due to either the lack of more than one or two radiotracers per isotope, the limited availability of the radionuclide in question, or decay characteristics that make the isotope sub-optimal for use in a clinical PET radiopharmaceutical.⁴⁰

The selection of a radiometal from the four main candidates, ^{64}Cu , ^{68}Ga , ^{86}Y , and ^{89}Zr , is a critical factor in determining the ultimate properties of a PET bioconjugate. In this regard, one of the most important considerations is matching the radioactive

half-life of the isotope to the biological half-life of the biomolecule. For example, ^{68}Ga is an inappropriate choice for labeling fully intact IgG molecules, for the radionuclide will decay through a number of half-lives before the antibody reaches its fully optimal biodistribution within the body. Therefore, the longer lived radiometals ^{64}Cu , ^{86}Y , and especially ^{89}Zr are most often employed for immunoPET with fully intact mAbs. That said, ^{68}Ga has been used successfully in the construction of PET bioconjugates based on antibody fragments with shorter biological half-lives. Conversely, ^{89}Zr would be an inappropriate choice for a short peptide radiotracer; in this case, the multi-day radioactive half-life of ^{89}Zr would far exceed what is typically a multi-hour biological half-life of the peptide, resulting in poor PET counting statistics and unnecessarily increased radiation dose to the patient. Thus, ^{64}Cu , ^{86}Y , and ^{68}Ga are most often employed for oligopeptide PET tracers. It is important to note that ^{64}Cu and ^{86}Y occupy a favorable middle ground with respect to radioactive half-life, allowing these radionuclides to be utilized advantageously in both antibody- and peptide-based tracers.

The production of radiometals in high radionuclidic purity and specific activity is essential to the development of effective bioconjugates for PET imaging, and while an in-depth understanding of the nuclear reactions and purification chemistry behind their production may not be necessary for the biomedical use of these isotopes, a brief overview of the processes surely has merit. The production methods for radionuclides fall into three general categories: generator, cyclotron, and nuclear reactor (Fig. 2). Of the positron-emitting radiometals addressed in this perspective, ^{68}Ga is generator-produced, while ^{64}Cu , ^{86}Y , and ^{89}Zr are produced using a medical cyclotron.

^{68}Ga is produced *via* the electron capture decay of its parent radionuclide, ^{68}Ge . In the laboratory and clinic, ^{68}Ga can be produced using a compact, cost-effective, and convenient $^{68}\text{Ge}/^{68}\text{Ga}$ generator system, which is capable of providing ^{68}Ga for PET tracers for 1–2 years before being replaced.⁶⁹ The ^{68}Ga is eluted from the generator in 0.1 M HCl, providing a $^{68}\text{GaCl}_3$ starting material for radiolabeling.⁷⁰ Despite its convenience, the system does have some limitations, most notably high eluent volumes that often must be pH-adjusted prior to radiolabeling reactions, ^{68}Ge break-through from the generator, and metal-based impurities. However, a number of purification techniques have been developed to circumvent the problems presented by the trace impurities in the ^{68}Ga eluent.

^{86}Y is the first of the three cyclotron-produced radiometals to be addressed here. ^{86}Y is most often produced through the $^{86}\text{Sr}(p,n)^{86}\text{Y}$ reaction *via* bombardment of an isotopically enriched

$^{86}\text{SrCO}_3$ or ^{86}SrO target with 8–15 MeV protons.^{71–74} A range of purification methods have been employed, including combinations of precipitation, ion exchange chromatography, chromatography with a Sr-selective resin, and electrolysis.^{75–77}

^{89}Zr has been produced *via* both the $^{89}\text{Y}(p,n)^{89}\text{Zr}$ and $^{89}\text{Y}(d,2n)^{89}\text{Zr}$ reactions. In the past, these methods have been used to successfully produce the radiometal using 13 MeV protons and 16 MeV deuterons, respectively, though both pathways have been complicated and limited by problematic purification protocols.^{78–80} A significant improvement upon these methods was provided by another production strategy that yielded ^{89}Zr *via* the bombardment of ^{89}Y on a copper target with 14 MeV protons, oxidation of Zr^0 to Zr^{4+} with H_2O_2 , and purification *via* anion exchange chromatography and subsequent sublimation steps.^{81,82} In the last few years, these methods have been improved upon further through the use of an ^{89}Y thin-foil target (99% purity, 0.1 mm width), the optimization of bombardment conditions (15 MeV, 15 μA , 10° angle of incidence), and an improved solid phase hydroxamate resin purification to produce ^{89}Zr reliably and reproducibly in very high specific activity (470–1195 $\mu\text{Ci}/\text{mmol}$) and radionuclidic purity (>99.99%).⁸³

Finally, ^{64}Cu can be produced with either a nuclear reactor or a cyclotron *via* a variety of reaction pathways.³ In a nuclear reactor, ^{64}Cu can be produced through the $^{63}\text{Cu}(n,\gamma)^{64}\text{Cu}$ and $^{64}\text{Zn}(n,p)^{64}\text{Cu}$ pathways. On a biomedical cyclotron, carrier-free ^{64}Cu can be produced using the $^{64}\text{Ni}(p,n)^{64}\text{Cu}$ and $^{64}\text{Ni}(d,2n)^{64}\text{Cu}$ reactions.^{84–88} The former pathway has proven more successful and is currently used to provide ^{64}Cu to research laboratories throughout the United States. In this method, the ^{64}Cu is processed and purified *via* anion exchange chromatography to yield no carrier-added $^{64}\text{Cu}^{2+}$. The expense of the enriched ^{64}Ni target is a limitation of this production pathway, though a technique for the recycling of ^{64}Ni has ameliorated this issue somewhat. In the last few years, a number of groups have worked to develop methods for the production of ^{64}Cu using Zn targets through the $^{64}\text{Zn}(d,2p)^{64}\text{Cu}$, $^{66}\text{Zn}(d,\alpha)^{64}\text{Cu}$, and $^{68}\text{Zn}(p,\alpha n)^{64}\text{Cu}$ reactions.^{89–92} These efforts have yielded some promising results but have failed to supplant the cyclotron-based $^{64}\text{Ni}(p,n)^{64}\text{Cu}$ pathway as the main route for ^{64}Cu production.

Radiometal chelation chemistry

With both the targeting vectors and radiometals in hand, the spotlight next falls on how to combine these two essential parts of the PET bioconjugate. Indeed, both the formation of a kinetically inert metal chelate and the stable covalent attachment of the




Fig. 2 Three methods for the production of radionuclides: (A) ^{68}Ga generator, (B) cyclotron, and (C) nuclear reactor. The authors acknowledge David Nickolaus of the Missouri University Research Reactor for the photo of the nuclear reactor.




Fig. 3 Selected chelators and bifunctional chelators for ^{64}Cu , ^{68}Ga , ^{86}Y , and ^{89}Zr .

chelator moiety to the biomolecule are essential to the creation of an effective radiopharmaceutical. To this end, a wide variety of metal-chelating molecules have been synthesized, studied, and, in many cases, made bifunctional to facilitate their conjugation

to a biomolecular vector (Fig. 3 and 4, *vide infra*). Transition metal chelators fall into two broad classes: macrocyclic chelators and acyclic chelators. Each has its own unique set of advantages: while macrocyclic chelators typically offer greater kinetic stability,




Fig. 4 Selected chelators and bifunctional chelators for ^{64}Cu , ^{68}Ga , ^{86}Y , and ^{89}Zr .

Table 3 Coordination number, donor set, and geometry^a for selected complexes of Cu(II), Ga(III), Y(III), and Zr(IV)³⁰

Metal	Chelator	Ligand Donor Set	Total CN	Coordination Geometry	Ref.
Cu(II)	DTPA	N ₃ O ₃	6	—	165
	NOTA	N ₃ O ₃	6	distorted trigonal prism	166, 167
	DOTA	N ₄ O ₂	6	distorted octahedron	168–170
	TETA	N ₄ O ₂	6	distorted octahedron	168–170
	CB-TE2A	N ₄ O ₂	6	distorted octahedron	101, 171
	EC	N ₂ S ₂	4	distorted square planar	172
	DIAMSA	N ₆	6	distorted octahedron or trigonal prism	173
Ga(III)	EDTA	N ₂ O ₄	6	distorted octahedron	174, 175
	HBED	N ₂ O ₄	6	—	176, 177
	DTPA	N ₃ O ₃	6?	—	175
	NOTA	N ₃ O ₃	6	distorted octahedron	168, 178
	DOTA	N ₄ O ₂	6	distorted octahedron	168
	TETA	N ₄ O ₂	6	distorted octahedron	168
	CB-TE2A	N ₄ O ₂	6	distorted octahedron	30, 179
	DFO	O ₆	6	—	180
Y(III)	DTPA	N ₃ O ₃	8	monocapped square antiprism	116, 181, 182
	DOTA	N ₄ O ₄	8	square antiprism	114, 116, 182
	TETA	N ₄ O ₂	8?	distorted dodecahedron(?)	183
Zr(IV)	DFO	O ₆	7 or 8	—	125
	DOTA	N ₄ O ₄	8?	square antiprism?	115
	EDTA	N ₂ O ₄	8	distorted dodecahedron	181, 184
	DTPA	N ₃ O ₃	8	distorted dodecahedron	181, 184

^a Question marks denote uncertainty in coordination number or geometry, and “—” denotes that the coordination geometry is not known.

acyclic chelators usually have faster rates of metal binding. Generally, transition metal chelators offer at least four (and usually six or more) coordinating atoms, arrayed in a configuration that suits the preferred geometry of the oxidation state and d-orbital electron configuration of the metal in question. Yet simply having a generic chelator with well-organized and plentiful donor atoms is not enough; in every case, an appropriate chelator must be chosen to suit the selected radiometal (Table 3). Of course, however, some (e.g. DOTA) are more universally applicable than others (e.g. DiamSar). The most relevant oxidation states for the metals discussed here are Zr(IV), Ga(III), Y(III), and Cu(II); *in vivo*, only Cu(II) is at significant risk for reduction reactions. In terms of the commonly-employed ‘hard-soft’ system of classification, Zr(IV) is considered a very hard cation, with Y(III) and Ga(III) close behind on the spectrum. Cu(II), which is a borderline acid, straddles the hard/soft border and is thus easily the softest of the four.

Cu(II) has a rich chelation chemistry, capable of the formation of four-, five-, and six-coordinate complexes, with geometries ranging from square planar to trigonal bipyramidal and octahedral.^{3,30,32,36,42,93} Due to its position on the border between hard and soft metals, Cu(II) exhibits a great affinity for nitrogen donors, though it is also known to bind either harder oxygen or softer sulfur donors as well. Generally, a copper chelator will feature a mixture of uncharged nitrogen and anionic oxygen or sulfur donors in order to neutralize the charge of the dicationic metal. Alone in solution, the metal forms a five-coordinate aquo-complex with rapid water-exchange rates that translate into facile

substitution reactions with other ligands.⁹⁴ Due to its 3d⁹ electronic structure, Cu(II) prefers a square planar coordination geometry. In consequence, both macrocyclic and acyclic tetradentate chelators have been developed for bioconjugation, including those with N₄ (e.g. cyclam), N₂O₂, and N₂S₂ (e.g. bis(aminothiolate)-based ligands) donor sets.^{95,96} Due to the critical importance of kinetic stability, however, the complexation of Cu(II) with its maximum of six donor atoms has become more popular than the use of tetradentate chelators. To this end, both six-coordinate macrocyclic and acyclic chelators have been employed with donor sets including N₂O₄ (e.g. EDTA), N₃O₃ (e.g. DTPA or NOTA), N₄O₂ (e.g. DOTA or CB-TE2A), and N₆ (e.g. SarAr, DiamSar, and AmBaSar).^{54,97–101} Of these options, CB-TE2A and the SarAr family seem to be particularly promising, given their high kinetic and thermodynamic stability. The possibility of the reduction of Cu(II) to Cu(I) under physiological conditions with certain ligand sets must also be noted. In some cases (e.g. ⁶⁴Cu-ATSM), this reduction may be essential to the pharmacodynamics of the radiotracer; however, in most situations, it is an extremely undesirable behavior that compromises the integrity of the radiopharmaceutical.²⁴

Smaller and harder than Cu²⁺, the Ga³⁺ cation typically binds ligands containing multiple anionic oxygen donors and adopts a coordination number of six, though complexes with four or five donor atoms are also known.^{36,38,44,102,103} Aqueous pH is particularly important in Ga³⁺ chelation chemistry: the low pK_a of the Ga(H₂O)₆³⁺ complex results in low solubility at physiological pH, while under basic conditions the affinity of the metal for hydroxide anions can result in its dissociation from chelators to form gallium hydroxide species. Tetradentate chelators with NO₃, NS₃, and N₂S₂ donor sets have been used.^{104–106} These polydentate ligands often combine with one or two water molecules or halides to place the metal in a distorted octahedral or distorted square pyramidal geometry; however, in some cases, the Ga³⁺ can adopt a simple four-coordinate distorted tetrahedral geometry. Acyclic and macrocyclic hexadentate chelators are more common for Ga³⁺, including those with N₂O₂S₂ (e.g. bis(aminothiolate)-based ligands), N₂O₄ (HBED), N₃O₃ (NOTA), N₃S₃ (TACN-TM), N₄O₂ (DOTA), and O₆ (DFO) donor sets.^{102,107–110} Complexes bearing these ligands almost always adopt a distorted octahedral geometry. Amongst these, DOTA is easily the most commonly employed in bioconjugates. However, the ligand has two drawbacks that limit its suitability for ⁶⁸Ga³⁺.¹¹¹ A central cavity that is too large for the cation limits the stability of the complex, and sluggish complexation kinetics require reaction times and temperatures that are less than ideally compatible with the short half-life of ⁶⁸Ga and the stability of some biomolecular constructs, respectively. In contrast, TACN-TM and HBED- and NOTA-based ligands are particularly promising chelation systems for ⁶⁸Ga due to their high thermodynamic and kinetic stability.^{103,112,113}

The chemistry of Y(III) provides a significant change of pace from the previous two metals. Much larger than the three other common PET radiometals, the closed-shell, hard Y³⁺ cation often reaches coordination numbers of eight or nine. Donor sets of N₂O₄ (EDTA), N₃O₃ (NOTAM), N₃O₅ (DTPA), N₄O₄ (DOTA), and N₄O₂ (TETA) have all been used to chelate the metal, with water molecules or other exogenous ligands filling the remaining coordination sites.^{114–117} The DOTA and DTPA ligands, however, form much more stable complexes with the metal than TETA and EDTA, indicating better chelator-metal matches in the former

cases. The higher coordination numbers also result in more exotic geometries: the DTPA complex adopts a monocapped square antiprism structure, the EDTA complex assumes a distorted dodecahedron geometry, and the DOTA complex results in a square antiprism structure. To date, DOTA- and DTPA-based chelators have been used in the vast majority of ^{86}Y bioconjugate strategies, though future studies will no doubt expand the range of chelating moieties employed in these tracers.^{118–120}

^{89}Zr is easily the most recent addition to the family of common PET radiometals, and the relative scarcity of aqueous chelation chemistry studies reflects this fact. The highly cationic Zr^{4+} center exhibits a strong preference for ligands bearing multiple anionic oxygens and can accommodate up to nine coordinating atoms. The metal makes eight-coordinate, dodecahedral complexes with DTPA (N_3O_5), EDTA (N_2O_4 with two additional water ligands), and DOTA (N_4O_4 , though the evidence here is less clear).^{121,122} However, the overwhelming majority of ^{89}Zr -bioconjugates employ DFO as the chelating ligand.^{123,124} No solid state or NMR structural studies are available, though DFT calculations suggest that seven- or eight-coordinate species involving one or two water molecules in addition to the ligand's six oxygen donors are most likely.¹²⁵ Given the considerable potential of ^{89}Zr as a PET radiometal, the continued development of novel high-stability chelating systems is needed.

Conjugation strategies

The final piece of the anatomy of a radiometal PET bioconjugate is the covalent attachment of the chelator to the biomolecule. This link must be stable under physiological conditions and must not significantly compromise the binding strength and specificity of the biomolecule. Three bond-types comprise the overwhelming majority of chelator-biomolecule attachments: peptide, thiourea, and thioether bonds (Fig. 5). The first of these three attachments is formed through the reaction of an activated carboxylic acid and a primary amine, the second *via* an isothiocyanate and an amine, and the third *via* a thiol and a maleimide. These are not, however, the only options for the conjugation reaction; the reactions of vinylsulfones with thiols, bromoacetamides with amines, and bromoacetamides with thiols have also been employed in more unique cases. Further still, and more recently, the set of bioorthogonal cycloaddition reactions, broadly termed “click chemistry” reactions, have also been applied to chelator conjugations (*vide infra*).

To facilitate the formation of these covalent links, bifunctional chelators are often employed. Bifunctional chelators are molecules bearing both metal-binding moieties and either reactive bond-making functionalities or pendant linker arms (Fig. 3 and 4). Given the preponderance of available primary amines and free thiols on many biomolecules, the corresponding activated ester, isothiocyanate, and maleimide groups are usually incorporated into the bifunctional chelator. These molecules can be synthesized and isolated from known chelators (*e.g.* DOTA-NHS from DOTA), designed and synthesized *de novo* as bifunctional chelators (*e.g.* *p*-SCN-Bn-DOTA), or generated *in situ* prior to or during the conjugation reaction (*e.g.* DOTA(*t*Bu)₃-NHS from DOTA(*t*Bu)₃). In some cases, the modification to a chelator that confers bifunctionality is made at a point that otherwise may have been a metal donor site, for example the addition of an activated

ester to a carboxylate arm in DOTA-NHS; in other situations, for example *p*-SCN-Bn-DOTA, a bifunctional linker is built into the backbone of the chelator so as to minimize any interference with the molecule's ability to bind to metal ions.

Both the number of chelates per biomolecule and the control over their placement can vary widely. The smaller size, well-established protecting group chemistry, and highly controlled and automated synthesis of peptide and nucleic acid vectors often allow for only a single chelator moiety, positioned at one terminus of the oligomer. In contrast, the method by which bifunctional chelators are typically conjugated to antibodies, *i.e.* the simple incubation of a given number of equivalents of bifunctional chelator with a solution of antibody, results in both a variable number of chelating moieties per antibody and their indeterminate placement on the macromolecule. The number of chelators per antibody can be determined fairly easily using isotopic dilution methods and can be controlled simply by altering the molar ratio of the bifunctional chelator in the conjugation reaction. Generally, more chelators per antibody is preferable, because higher specific activities can be attained. The control and knowledge of chelator placement, however, is harder to come by; the apprehension here, of course, is that the presence of a chelator in the binding region of the antibody can negatively effect its ability to bind to the antigen. Therefore, the goal in antibody conjugation is simple: attach as many chelators per antibody as possible, without compromising the immunoreactivity of the biomolecule.

Significantly, the conjugation of the chelator is almost always performed prior to radiometallation. Thus, the final step in the construction of a PET radiometal bioconjugate is the radiolabeling of the biomolecule-linker-chelator construct. The goal of this final step is the incorporation of as much activity as possible, as quickly as possible, without damaging the biomolecule. Therefore, temperature and pH conditions that favor rapid metallation reactions must be balanced against the concern for the integrity of the biomolecule. For example, while metallating a DOTA-conjugated antibody with ^{64}Cu may proceed most quickly and efficiently at 90 °C, such high temperatures risk denaturing the antibody, and lower temperatures should be employed as a result.

In the preceding pages, it has become clear that the imaging scientist has many choices to make and factors to consider in the development and construction of a radiometal-based PET bioconjugate. In the final section of this perspective, we will provide a practical overview of the design and synthesis strategies used for PET bioconjugates currently described in the literature.

The construction of ^{68}Ga bioconjugates

The short half-life and facile production of ^{68}Ga have made it one of the radionuclides of choice for peptide-based PET bioconjugates.¹²⁶ Tracers have been developed to target a wide array of cancer biomarkers, including epidermal growth factor receptor (EGFR), gastrin releasing peptide receptor (GRPR), integrin $\alpha_v\beta_3$, and melanocortin-1 receptor (MC1-R).^{127–130} However, the ^{68}Ga peptide bioconjugates that have had the greatest impact in the clinic are without question the family of ^{68}Ga -somatostatin analogues (SST).^{131–134} SST-receptors (SSTR) are over-expressed in neuroendocrine tumors, prostate carcinomas, breast carcinomas, lymphomas, and small-cell lung cancers, among others, and




Fig. 5 The three principal types of bioconjugation reactions: (A) peptide bond formation *via* reaction of a primary amine with a carboxylic acid activated with a succinimidyl ester (NHS), a sulfo-succinimidyl ester (SNHS), tetrafluorophenol (TFP), or a peptide coupling reagent (*e.g.* HATU, HOBT, *etc.*); (B) thioether bond formation *via* reaction of a thiol and a maleimide; and (C) thiourea bond formation *via* reaction of an isothiocyanate and a primary amine.

⁶⁸Ga-somatostatin analogues, particularly ⁶⁸Ga-DOTATOC, have been used to great effect in the imaging of these malignancies (Fig. 6).¹³⁵

A wide variety of chelators, conjugation strategies, and metallation procedures have been employed in the synthesis of ⁶⁸Ga-labeled peptides (see Table 4 for experimental details and references). DOTA and NOTA-conjugated peptides are most common by a wide margin, though HBED and DFO have also been used. Given the solid-phase synthesis of many peptides, the conjugation of the chelator to the peptide is often performed while the peptide is still attached to a solid resin support. This can be achieved *via* the manual manipulation of the peptide-coated resin and subsequent incubation with a bifunctional chelator, or using

an automated peptide synthesizer. In the latter scenario, a pre-prepared bifunctional chelator is not needed; rather, a monoreactive precursor is added to the automated synthesizer and is coupled to the growing peptide chain *via* an activated, bifunctional intermediate. Despite the preponderance of solid-phase methods, a number of *in situ* conjugations have also been reported using bifunctional chelators such as DOTA-NHS, HBED-CC-NHS, *p*-SCN-Bn-NOTA, and NH₂-Bn-NOTA. Generally, peptide and isothiocyanate-based conjugations are performed at a slightly basic pH (8–9.5), due to the participation of a deprotonated primary amine in the bond-forming reactions. Further still, the peptide-chelator conjugates are almost always purified *via* RP-HPLC or C₁₈ cartridge prior to radiolabeling.




Fig. 6 A 78-year-old woman with neuroendocrine tumor of unknown primary origin: (A) ^{68}Ga -DOTATOC PET depicts diffuse bone metastases, (B) CT shows only part of widespread bone involvement, and (C) the structure of ^{68}Ga -DOTATOC. Reprinted by permission of the Society of Nuclear Medicine from: D. Putzer, M. Gabriel, B. Henninger, D. Kendler, C. Uprimny, G. Dobrozemsky, C. Decristoforo, R. J. Bale, W. Jaschke and I. J. Virgolini, *Journal of Nuclear Medicine*, 2009, **50**, 1214–1221. Fig. 2.¹⁵⁵

The metallation procedures for the peptide-chelator constructs follow the same general course, though the experimental details can vary considerably. The most common buffers for the metallation reaction are NaOAc, HEPES, $\text{NaH}_2\text{PO}_4/\text{Na}_2\text{HPO}_4$, and $\text{Na}_2\text{CO}_3/\text{NaHCO}_3$, and these are used in concentrations ranging from 0.1 M to 0.5 M. The pH for the reaction depends on the chelator: 5–6 for NOTA-based chelators, 3.8–5.5 for DOTA-based chelators, 4–5 for HBED, and 4–5 for DFO. Reaction times and temperatures likewise vary depending on the chelator employed, ranging from 5 min at room temperature for DFO to 25 min at 95 °C and 20 min at 100 °C for DOTA. Often, the radiolabeling reaction is quenched by the addition of free chelator to scavenge excess unreacted radiometal. Finally, the purification of the resultant radiolabeled peptides is most often achieved using C_{18} cartridges (e.g. Waters Sep-PakTM), RP-HPLC, or size exclusion chromatography.

^{68}Ga has also been used for the labeling of antibody fragments and affibody molecules, though far fewer examples exist than for ^{68}Ga -peptides (see Table 5 for experimental details and references). In these cases, HBED, DOTA, and DTPA have been employed as the chelators of choice. The conjugation reactions are usually performed *via* the incubation of a solution of antibody fragment with a bifunctional chelator, such as DOTA-NHS or HBED-CC-TFP; however, in the case of one affibody construct, solid

phase peptide synthesis and a monoreactive chelator precursor are used as described above for the peptide-based conjugates. Again, all of the macromolecules are purified subsequent to conjugation in order to remove excess chelator. Despite the relatively few examples, the metallation reactions are performed using an array of buffer types (HEPES, phosphate, and NH_4OAc) and concentrations (0.1 M to 1.25 M). The time, temperature, and pH of the metallation reactions are all dependent on the identity of the chelator, though in a few cases, these conditions are not noted in the literature. After a suitable incubation, the radiolabeling reaction is often quenched with the addition of free chelator, and in all cases, the resultant radiometallated conjugate is purified with size exclusion chromatography. It thus becomes clear that the labeling of antibody fragments does not yet have standardized methodologies, which is a limitation that will be resolved as more examples of these extremely promising radiotracers come to light.

Finally, a small number of oligonucleotide-based ^{68}Ga -labeled bioconjugates have also been developed (see Table 6 for experimental details and references).^{136–138} 2'-Deoxyphosphodiester (PO), 2'-deoxyphosphorothioate (PS), 2'-*O*-methyl phosphodiester (OMe), and locked nucleic acid (LNA) oligonucleotides have been synthesized and radiolabeled for gene expression imaging. In all cases, DOTA has been used as the chelator for ^{68}Ga and is incorporated into the oligonucleotide using a DOTA-SNHS bifunctional chelate. Metallations have been performed in either NaOAc or HEPES buffer at pH 4.5–5.5, using short incubations at 90–100 °C (in some cases, microwave-assisted). Finally, the completed, radiolabeled oligonucleotides are typically purified with reverse-phase C_4 or C_{18} cartridges (e.g. Waters Sep-PakTM).

The construction of ^{64}Cu bioconjugates

Given its intermediate half-life, favorable decay properties, relative accessibility, and well-established chelation chemistry, ^{64}Cu has become a versatile and widely utilized radiometal for bioconjugate tracers. A variety of ^{64}Cu -peptides have been developed, targeting biomarkers including SSTR, integrin $\alpha_v\beta_3$, GRPR, MC1-R, integrin $\alpha_4\beta_1$, formyl peptide receptor (FPR), natriuretic peptide receptor (NPR), and vascular endothelial growth factor receptor (VEGFR), among many others (Fig. 7, see Table 7 for experimental details and references). The chelators employed in these conjugates are almost as diverse as the peptides themselves, with DOTA and CB-TE2A leading the way, but with TETA, NOTA, BPM-TACN, and DiamSar also used in some agents. As in the ^{68}Ga peptides, both solid- and solution-phase chelator conjugation strategies have been used. For those involving bifunctional chelators, peptide and isothiocyanate-based conjugations are typically performed at slightly basic pH (8–9.5), because these reactions require a deprotonated primary amine to proceed. Also like the ^{68}Ga cases, the post-conjugation purification of the peptide-chelator construct by RP-HPLC or C_{18} cartridge is a common practice. The buffers most often chosen for radiometallations are NH_4OAc and NaOAc, typically utilized at concentrations ranging from 0.1 M to 0.5 M. However, incubation time, temperature, and pH vary according to the chelator. For example, the radiolabeling of DOTA-based conjugates is typically performed at pH 5–6.5 with 30–60 min incubations at temperatures ranging from room temperature to 95 °C. In contrast, the metallation of DiamSar-based conjugates can be performed at pH 8.0 with a 60 min

Table 4 Guide to the construction of ^{68}Ga -peptide bioconjugates

Chelator	Target	Conjugation	Radiometallation ^a	Purification
DOTA	VAP-1 ¹⁸⁵	Peptide was coupled on the bead to DOTA(tBu) ₃ using an automated peptide synthesizer. Removal of the peptide from the support, deprotection, and RP-HPLC followed.	^{68}Ga eluent was adjusted to pH 5.5 with NaOAc, followed by addition of the peptide and incubation for 10–20 min at 90–100 °C.	None reported
	EGFR ¹²⁷	Peptide in borate buffer (0.08 M, pH 9.4) was added to dry DOTA-NHS. The pH of the resultant solution was adjusted to 9.0 with additional borate, and the mixture was allowed to stir overnight at RT, followed by RP-HPLC.	Peptide was incubated with ^{68}Ga for 1 min at 90 °C <i>via</i> microwave in either NaOAc (pH 5.0, for use with non-concentrated eluent) or HEPES (pH 4.7, for use with concentrated eluent).	C ₁₈ cartridge
	GRPR ^{128,186}	Peptide on resin was mixed with a pre-incubated solution of DOTA(tBu) ₃ and HATU in <i>N</i> -methylpyrrolidone (adjusted to pH 7–8 using DIPEA), followed by cleavage from resin, deprotection, and purification.	^{68}Ga eluent was dried and redissolved in NaOAc (0.1 M, pH 4.8), followed by addition of the peptide and incubation for 10 min at 90 °C.	C ₁₈ cartridge
	NTR ¹⁸⁷	Peptide was coupled on the bead to DOTA(tBu) ₃ using an automated peptide synthesizer. Removal of the peptide from the support, deprotection, and purification followed.	Peptide was incubated with ^{68}Ga in NaOAc (concentration not noted, pH 4.5) for 10 min at 95 °C.	None reported
	SSTR ^{126,188,189} GRPR ¹²⁶	Peptide was coupled on the bead to DOTA(tBu) ₃ using an automated peptide synthesizer. Removal of the peptide from the support, deprotection, and purification followed.	^{68}Ga eluent was adjusted to pH 3.5–3.8 with 1 M HEPES and incubated with the peptide for 4 min at 90 °C.	C ₁₈ cartridge
	GRPR ^{190,191}	Peptide was coupled on the bead to DOTA(tBu) ₃ with HATU using an automated peptide synthesizer. Removal of the peptide from the support, deprotection, and purification followed.	^{68}Ga eluent was dried and redissolved in NaOAc (0.1 M, pH 4.8), followed by addition of peptide and incubation for 10 min at 90 °C.	C ₁₈ cartridge
	MC1-R ^{192,193}	Deprotected peptide was dissolved in DMF with DIEA (1.5%) and added to a solution of DOTA(tBu) ₃ and HATU, which had been incubated in DMF for 10 min at RT. The resultant solution was stirred at RT for 1 h, followed by precipitation, deprotection, and RP-HPLC.	Peptide was incubated with ^{68}Ga in NaOAc (0.1 M, pH 4.8) for 15 min at 90 °C.	C ₁₈ cartridge
	SSTR ^{132,133}	DOTA(tBu) ₃ , HATU, and DIEA (1 : 1 : 1) were incubated with DMF for 10 min at RT, followed by addition of the peptide (in DMF with 1.5% DIEA) and stirring for 4 h at RT. Extraction, deprotection, and RP-HPLC followed.	Peptide was incubated with ^{68}Ga in NaOAc (0.4 M, pH 4.8–5.5) for 15–25 min at 95 °C.	C ₁₈ cartridge
	SSTR ¹³⁴	Conjugate was purchased from a commercial supplier.	Peptide was incubated with ^{68}Ga in NaOAc (0.1 M, pH 4.5) for 5 min at 95 °C.	C ₁₈ cartridge
	SSTR ¹³⁵	Conjugate was purchased from a commercial supplier.	^{68}Ga eluent in 0.05 M HCl/acetone (2 : 98) was added directly to the peptide in water and incubated for 10 min at 100 °C.	C ₁₈ cartridge

Table 4 (Contd.)

Chelator	Target	Conjugation	Radiometallation ^a	Purification
	SSTR ¹⁴⁸	Hydroxylamine-modified peptide was incubated with deprotected acetyl-Bn-DOTA in 1 : 1 CH ₃ CN : H ₂ O (adjusted to pH 4 with TFA) for 18 h at RT, followed by RP-HPLC.	Experimental details were not given, though radiometallation was reported in publication.	None noted
HBED	VEGFR ¹⁹⁴	1. Formation of the activated ester of Fe(HBED-CC) complex with NHS and EDC in DMF-H ₂ O 2. Reaction of Fe-HBED-CC-NHS with NH ₂ -PEG-maleimide in MES buffer (0.5 M, pH 8.0) for 30 min at RT, followed by RP cartridge (1 M HCl) to remove Fe ³⁺ 3. Reaction of HBED-CC-PEG-maleimide with deprotected peptide in carbonate buffer (pH 8.0) for 1 h 4. Purification <i>via</i> C ₄ RP-HPLC	Peptide solution (0.1 M phosphate buffer, pH 7.0) was combined with 10 µL ⁶⁸ Ga solution and 10 µL 2.1 M HEPES, for a final pH of 4.2. Time and temperature were not noted.	Size exclusion chromatography
NOTA	VEGFR ^{194,195}	Peptide modified with NHS-PEG group was incubated with <i>p</i> -NH ₂ -Bn-NOTA in carbonate buffer (pH 8.0) for 1 h, followed by C ₄ RP-HPLC.	Same as above	Size exclusion chromatography
	α _v β ₃ ^{129,196} GRPR ¹⁹⁶	Peptide was incubated with <i>p</i> -SCN-Bn-NOTA in NaHCO ₃ (0.1 M, pH 9.0) for 5 h at RT, followed by RP-HPLC.	Peptide was incubated with ⁶⁸ Ga in NaOAc (0.1 M, pH 5) for 10–15 min at 40–45 °C.	RP-HPLC
	α _v β ₃ ¹⁹⁷	Peptide was incubated with <i>p</i> -SCN-Bn-NOTA in NaHCO ₃ (0.1 M, pH 9.5) for 20 h at RT, followed by RP-HPLC.	⁶⁸ Ga eluent was adjusted to pH 6.0 with 7% NaHCO ₃ solution, followed by addition of peptide for 10 min at RT.	RP-HPLC
	SSTR ¹³¹	Peptide on resin was mixed with a pre-incubated solution of NODAGA(tBu) ₃ and HATU in <i>N</i> -methylpyrrolidone (adjusted to pH 7–8 using DIPEA), followed by cleavage from resin, deprotection, and RP-HPLC.	Peptide was incubated with ⁶⁸ Ga in NaOAc (0.4 M, pH 5) or HEPES (0.1 M, pH 5.8) for 25 min at 95 °C	C ₁₈ cartridge
DFO	SSTR ¹⁹⁸	Peptide bearing an activated succinimidyl ester was incubated with DFO mesylate in DMF with DCC/HOBT. Time, temperature, and intermediate purification were not noted.	Peptide (in 0.1% AcOH) was incubated with ⁶⁸ Ga (in 0.1 M NH ₄ OAc, pH 4.5) for 5 min at RT.	None reported
DTPA	LDL ^{199,200}	Peptide was reacted with cyclic DTPA anhydride in HEPES buffer (0.1 M, pH 7) for 30 min at RT, followed by size exclusion chromatography. Other buffer types were reported to work for this reaction as well.	⁶⁸ Ga eluent was dried and re-dissolved in NaOAc (0.4 M, pH 7.0), followed by addition of peptide and incubation for 1–30 min at RT.	Size exclusion chromatography
	None (HSA) ²⁰¹	Peptide was incubated with mixed acid anhydride DTPA in aqueous buffer (type and concentration not noted) for 12 h at 4 °C, followed by size exclusion chromatography.	DTPA-HSA solution pH was lowered to 3.1 with 1 M HCl, followed by addition of ⁶⁸ Ga solution (in 1 : 3 EtOH:0.9% NaCl), incubation at RT for 30 min, and final adjustment of pH to 5.5 with 0.1 M NaOH.	Size exclusion chromatography

^a Some protocols call for the use of gentisic acid (typically 1–5 mg mL⁻¹) to protect the biomolecule from radiolysis.

Table 5 Guide to the construction of ^{68}Ga -antibody bioconjugates

Chelator	Target	Conjugation	Radiometallation ^a	Purification
HBED	EGFR ¹¹² EpCAM ^{112,202}	1. Synthesis of Fe(HBED-CC) 2. Formation of an activated ester of the Fe(HBED-CC) complex <i>via</i> reaction with TFP and DCC in DMF for 2 d at RT, followed by HPLC purification and removal of Fe ³⁺ with RP-cartridge using 1 M HCl 3. Incubation of HBED-CC-TFP (from DMSO stock) with antibody fragment in carbonate/phosphate buffer (pH 8) for 30 min at RT, followed by size exclusion chromatography.	Antibody solution (0.1 M phosphate buffer, pH 7.0) was combined with ^{68}Ga eluent and 2.1 M HEPES (for a final pH of 4.1–4.5) and incubated for 5–10 min at RT (40 °C).	Size exclusion chromatography
DOTA	HER2 ^{203–205}	Active DOTA ester was first formed <i>via</i> reaction of DOTA with NHS and subsequently EDC at RT, followed by cooling to 4 °C for 1 h and incubation with antibody fragment solution (0.1 M sodium phosphate, pH 7.0) overnight at 4 °C. Excess DOTA was removed with centrifugal filtration.	Antibody solution (in 1 M NH ₄ OAc stock) was combined with ^{68}Ga eluent (in 0.1 M HCl) and incubated for 15 min at 37 °C. Final reaction pH was not noted.	Size exclusion chromatography
	HER2 ^{206–208}	Affibody was synthesized using standard solid phase synthesis and Fmoc chemistry, followed by conjugation on the bead with DOTA(tBu) ₃ -NHS and subsequent deprotection, removal from the bead, and purification.	^{68}Ga eluent (in 0.1 M HCl) was combined (~1 : 1) with affibody in NH ₄ OAc (1.25 M, pH 4.2) and incubated for 10 min at 90 °C.	None noted
DTPA	hPSP ^{209,210}	Antibody was incubated with DTPA cyclic anhydride in aqueous solution (buffer conditions not described), followed by size exclusion chromatography to remove excess DTPA.	^{68}Ga eluent was evaporated to dryness, reconstituted in NH ₄ OAc buffer (0.1 M), and incubated with antibody. Time, pH, and temperature were not noted.	Size exclusion chromatography
DTPA	CD45 ²¹¹	Antibody was incubated with <i>p</i> -SCN-DTPA, mx-DTPA, or CHX-A''-DTPA in HEPES buffer (0.05 M, pH 9.5) for 20 h at RT, followed by size exclusion chromatography.	^{68}Ga eluent pH was adjusted to ~5 with 1 M NaOAc, followed by addition of antibody for 10 min at RT. Reaction was quenched with DTPA.	Size exclusion chromatography

^a Some protocols call for the use of gentisic acid (typically 1–5 mg mL⁻¹) to protect the biomolecule from radiolysis.




Fig. 7 Coronal microPET images with co-registered CT of mice bearing PC-3 xenografts in the axillary thorax at (A) 1 h and (B) 24 h. The mice were injected *i.v.* with a GRPR-targeting ^{64}Cu -bombesin analogue, ^{64}Cu -DOTA-GSS-BN(7–14). The mice on the left (A) were not injected with blocking agent, while the mice on the right (B) received 100 μg of Tyr⁴-BN as an inhibitor. Adapted with permission from J. J. Parry, T. S. Kelly, R. Andrews and B. E. Rogers, *Bioconjugate Chemistry*, 2007, **18**, 1110–1117.¹⁵⁶ Copyright 2007 American Chemical Society.

incubation at room temperature. In many cases, unreacted ^{64}Cu is scavenged after radiolabeling with free chelator (*e.g.* EDTA or

DTPA), and after the successful radiometallation reaction, the overwhelming majority of the ^{64}Cu -peptide conjugates are purified using RP-HPLC.

The 12.7 h half-life of ^{64}Cu has allowed it to be utilized in antibody-based conjugates as well as those derived from peptides (see Table 8 for experimental details and references). Indeed, ^{64}Cu -labeled antibody radiotracers have been developed against an array of biomarker antigens, for example human epidermal growth factor receptor 2 (HER2), prostate specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and carcinoembryonic antigen (CEA). As with the ^{64}Cu -peptides, a number of chelators have been used, including DOTA, CPTA, DO3A, TETA, and SarAr. The conjugation strategies for antibodies rely almost exclusively on incubation with bifunctional chelators, either generated *in situ* or synthesized and isolated (or purchased) beforehand. As is now clearly becoming a trend, the antibody-chelator constructs are almost always purified after conjugation by size exclusion chromatography or centrifugation with a high molecular weight filter membrane. The metallation procedures closely resemble those used for ^{64}Cu -peptides: the most common buffers are NaOAc, NH₄OAc, and NH₄-citrate at concentrations of 0.1–0.25 M. The incubation time, temperature, and pH vary according to chelator; however, the incubation temperatures seldom rise above 43 °C due to concerns over antibody stability. Again, in many cases, unreacted ^{64}Cu is scavenged after radiolabeling with free chelator (*e.g.* EDTA or DTPA). Finally, the radiometallated antibody bioconjugates are typically purified *via* size exclusion chromatography (*e.g.* HPLC,

Table 6 Guide to the construction of radiometallated oligonucleotide bioconjugates

Chelator	Nuclide	Type	Conjugation	Radiometallation	Purification
DOTA	^{86}Y	RNA oligomer ¹²⁰	Amine-modified oligomer was incubated with <i>p</i> -SCN-Bn-DOTA in NaHCO_3 buffer (0.7 M, pH 9.0) for 2 h at 40 °C, followed by purification <i>via</i> EtOH precipitation and size exclusion chromatography.	Oligomer was incubated with ^{86}Y in NH_4OAc buffer (0.5 M, pH 7.0) for 30–60 min at 90 °C. Reaction quenched with DTPA.	RP-HPLC
	^{86}Y	RNA oligomer ¹³⁸	Amine-modified oligomer was incubated with DOTA-NHS in NaHCO_3 buffer (0.7 M, pH 8.1) for 2 h at 40 °C, followed by purification <i>via</i> size exclusion chromatography.	Oligomer was incubated with ^{86}Y in NH_4OAc buffer (0.5 M, pH 6.0) for 45 min at 90 °C. Reaction quenched with DTPA.	C_{18} cartridge
	^{64}Cu	PNA-peptide conjugate ^{55,212}	Amine-modified PNA/peptide conjugate on a solid support was reacted with DOTA(<i>t</i> Bu) ₃ and HATU on a peptide synthesizer for 60 min, followed by cleavage, deprotection, and RP-HPLC.	Conjugate was incubated with ^{64}Cu in NH_4OAc buffer (0.1 M, pH 5.5) for 15 min at 90 °C.	RP-HPLC
	^{64}Cu	PNA ²¹³	DOTA(<i>t</i> Bu) ₃ (in <i>N</i> -methylpyrrolidone) was combined with HATU (in DMF) and base (DIEA and 2,6-lutidine in DMF) and subsequently manually reacted with resin-bound PNA for 1 h at RT, followed by cleavage, deprotection, and RP-HPLC.	$^{64}\text{CuCl}_2$ was converted to ^{64}Cu -citrate with NH_4 -citrate (0.1 M, pH 7.0) and incubated with PNA in buffer for 1–2 h at 60 °C. Reaction quenched with DTPA.	Centrifugal column filtration
	^{68}Ga	RNA oligomer ¹³⁸	Amine-modified oligomer was incubated with DOTA-NHS in NaHCO_3 buffer (0.7 M, pH 8.1) for 2 h at 40 °C, followed by purification <i>via</i> size exclusion chromatography.	Oligomer was incubated with ^{68}Ga in NH_4OAc buffer (0.5 M, pH 4.1–4.7) for 45 min at 90 °C. Reaction quenched with DTPA.	C_{18} cartridge
	^{68}Ga	DNA, PS, and OMe oligomers ^{137,214}	Activated ester was formed <i>via</i> the incubation of DOTA with SNHS and EDC in H_2O from 4 °C to RT over 30 min. This mixture was added to amine-modified oligonucleotide solution in carbonate buffer (1 M, pH 9) overnight at 4 °C, followed by purification <i>via</i> size exclusion chromatography and C_{18} cartridge.	^{68}Ga eluent was adjusted to pH 5.5 with NaOAc , followed by addition of oligonucleotide for 10 min at 100 °C.	C_{18} cartridge
	^{68}Ga	DNA-LNA oligomer ^{136,214}	Amine modified oligomer was incubated with DOTA-SNHS in $\text{Na}_2\text{B}_4\text{O}_7$ buffer (adjusted to pH 8.5–10 with 5 M NaOH) overnight at 4 °C, followed by purification by centrifugal column filtration.	Oligomer was added to purified ^{68}Ga eluent (HEPES, pH 4.6–5.0) and heated to 90 °C for 1 min in a microwave.	C_4 cartridge
SBTG ₂ DAP	^{64}Cu	PNA-peptide conjugate ²¹⁵	Using an automated peptide synthesizer, diaminopropanoate-modified PNA/peptide conjugate on a solid support was reacted with two equivalents of <i>S</i> -benzoyl thioglycolic acid using HATU and <i>N</i> -methylmorpholine in DMF.	Conjugate was incubated with ^{64}Cu in NH_4OAc buffer (0.1 M, pH 5.5) for 30 min at 90 °C.	RP-HPLC

FPLC, or GE Life Sciences PD-10 columns) or centrifugal column filtration (*e.g.* Amicon Ultra-4 30,000 MWCO centrifugal filtration units).

A small number of peptide nucleic acid (PNA) and hybrid PNA-oligopeptide ^{64}Cu -labeled conjugates have also been created for mRNA-targeted imaging (see Table 6 for experimental details and references). These conjugates have employed either DOTA or SBTG₂DAP as the chelating moieties, with solid-phase Fmoc synthesis techniques analogous to those for peptides used to incor-

porate the chelators into the oligomers. Radiolabeling reactions have been performed in either NH_4OAc or NH_4 -citrate buffer (pH 5.5–6.0), with incubations of 15–120 min at temperatures ranging from 60 to 90 °C.

The construction of ^{86}Y bioconjugates

The intermediate half-life, well-studied chelation chemistry, and presence of a radiotherapeutic isotopologue in ^{90}Y all make ^{86}Y a

Table 7 Guide to the construction of ^{64}Cu -peptide bioconjugates

Chelator	Target	Conjugation ^a	Radiometallation ^{b,c}
DOTA	GRPR ^{156,216,217} SSTR ²¹⁸	Peptide was coupled to DOTA(tBu) ₃ or DOTA(tBu) ₃ -NHS using an automated peptide synthesizer and standard Fmoc chemistry, followed by cleavage from the resin, deprotection, and purification.	Peptide was incubated with ^{64}Cu in NH ₄ OAc (0.1 M, pH 5.5) for 30 min at RT.
	MC1-R ^{219,220}	Peptide was coupled to DOTA(tBu) ₃ using an automated peptide synthesizer and standard Fmoc chemistry, followed by cleavage from the resin, deprotection, and purification.	Peptide was incubated with ^{64}Cu in NaOAc (0.1 M, pH 5.5) for 60 min at 65 °C.
	GRPR ²²¹	Peptide was coupled to DOTA(tBu) ₃ while still on the peptide synthesizer, followed by cleavage from resin, deprotection, and purification.	Peptide was incubated with ^{64}Cu in NH ₄ OAc (0.4 M, pH 7) for 40 min at 70 °C.
	$\alpha_v\beta_6$ ²²²	Peptide was coupled to DOTA(tBu) ₃ using HATU/DIEA while peptide was still on the resin, followed by cleavage from the resin, deprotection, and purification.	Peptide was incubated with ^{64}Cu in NH ₄ OAc (1 M, pH 7–8) for 60 min at RT. Reaction quenched with EDTA.
	GRPR ²²³	The method of DOTA incorporation method is unclear; however, a tributyl anhydride of DTPA was used for the acylation of prolines in similar DTPA-modified conjugates, so a similar strategy may have been used here.	Peptide was incubated with ^{64}Cu in NH ₄ OAc (0.5 M, pH 6.5) for 30 min at 80 °C.
	$\alpha_v\beta_3$ ^{224–228} GRPR ²²⁹ VEGFR ^{230,231} UPar ²³² IL-18R ^{233,c}	DOTA was activated for coupling <i>via</i> reaction with EDC and <i>N</i> -hydroxysulfosuccinimide (SNHS) (10 : 5 : 4) in water (pH 5.5) for 30 min at 4 °C. Peptide (in water, buffer, or saline) was then added to the solution, the pH was adjusted to 8.5 with 0.1 M NaOH, and the resultant solution was stirred for 16 h at 4 °C.	Peptide was incubated with ^{64}Cu in NaOAc (0.1 M, pH 5–6.5) for 30–60 min at 40–50 °C. In some cases the reaction was quenched with EDTA.
	MC1-R ^{234,235} $\alpha_v\beta_3$ ^{235,c}	DOTA was activated for coupling <i>via</i> reaction with EDC and SNHS (1 : 1 : 0.8) in water (pH 5.5) for 30 min at 4 °C. Peptide (in phosphate buffer or water) was then added to the solution, the pH was adjusted to 8.5–9.0 with 0.1 M NaOH, and the resultant solution was stirred for 16 h at 4 °C.	Peptide was incubated with ^{64}Cu in NaOAc (0.1 M, pH 5.5) for 60 min at 37–50 °C.
	$\alpha_v\beta_3$ ²³⁶	DOTA was initially activated for coupling <i>via</i> 1 : 1 : 1 reaction with SNHS and EDC in water (pH 5.5) for 40 min at RT. Peptide in phosphate buffer (30 mM, pH 8.5) was then added to the solution, the pH was adjusted to 8.5 with 0.1 M NaOH, and the resultant solution was stirred for 1 h at RT and then 16 h at 4 °C.	Peptide was incubated with ^{64}Cu in NaOAc (0.1 M, pH 6.3) for 60 min at 45 °C. ^c
	$\alpha_v\beta_3$ ²²⁴	Peptide was incubated with (tBu) ₃ DOTA, HBTU, and Hunig's Base in DMF overnight at RT, followed by deprotection, and purification.	Peptide was incubated with ^{64}Cu in NaOAc (0.5 M, pH 5.5) for 45 min at 50 °C.
	NPR ^{237,238}	Peptide was incubated with DOTA-NHS overnight in Na ₂ HPO ₄ buffer (0.1 M, pH 7.5) at RT.	Peptide was incubated with ^{64}Cu in NH ₄ OAc (0.1 M, pH 5.5) for 60 min at 43 °C.
	GC-C ²³⁹	Peptide was incubated with DOTA-NHS in HEPES buffer (0.3 M, pH 8.5) overnight at 4 °C.	Peptide was incubated with ^{64}Cu in NH ₄ OAc (0.4 M, pH 6.0) for 1 h at 80 °C. Reaction quenched with EDTA.
	FPR ²⁴⁰	Peptide was incubated with DOTA-NHS in water (pH 8.5) overnight at 4 °C.	Peptide was incubated with ^{64}Cu in NH ₄ OAc (0.1 M, pH 5.5) for 30 min at 40 °C.
	VEGFR ^{195,241}	<i>p</i> -NH ₂ -Bn-DOTA was activated <i>via</i> reaction with NHS-PEG-maleimide in buffer (15 mM NaOAc, 50 mM Na ₂ CO ₃ , 115 mM NaCl, pH 8.0) at RT for 1 h, followed by quenching of excess maleimide with Tris HCl (1 M, pH 8.0), the addition of peptide, incubation for 1 h at RT, and RP-HPLC with a C ₄ column. ^d	Peptide was incubated with ^{64}Cu in NaOAc (0.1 M, pH 5.3–5.5) for 60 min at 55 °C. Reaction quenched with EDTA. ^d
	Low pH ²⁴²	Peptide was incubated with DOTA-maleimide in PBS (pH 7, with 2 mM EDTA) overnight at 4 °C. ^d	Peptide was incubated with ^{64}Cu in NH ₄ OAc (0.5 M, pH 5.5) for 30 min at RT. Reaction quenched with EDTA.

Table 7 (Contd.)

Chelator	Target	Conjugation ^a	Radiometallation ^{b,c}
CB-TE2A	MC1-R ²⁴³	Peptide was coupled to CB-TE2A using standard Fmoc/HBTU chemistry on a peptide synthesizer, followed by cleavage from the resin and deprotection.	Peptide was incubated with ⁶⁴ Cu in NH ₄ OAc (0.1 M, pH 8) for 60 min at 95 °C.
	SSTR ²⁴⁴	Peptide was reacted while still on the resin with CB-TE2A that had been pre-activated with DIEA and DCC, followed by cleavage from the resin, deprotection, and purification.	Peptide was incubated with ⁶⁴ Cu in NH ₄ OAc (0.1 M, pH 8) for 90 min at 95 °C.
	SSTR ^{50,245}	CB-TE2A was dissolved in DMF with DIEA and DIC and stirred for 25 min at RT before adding the solution to the peptide-containing resin. The resultant mixture was agitated for 3 h before filtration, washing, cleavage, and purification.	Peptide was incubated with ⁶⁴ Cu in NH ₄ OAc (0.1 M, pH 8) for 60–90 min at 95 °C.
	$\alpha_4\beta_1$ ²⁴⁶	CB-TE2A was dissolved in DMF with DIEA and DIC and stirred for 25 min at RT before adding the solution to the peptide-containing resin. The resultant mixture was agitated overnight before filtration, washing, cleavage, and purification.	Peptide was incubated with ⁶⁴ Cu in NH ₄ OAc (0.14 M, pH 7) for 60 min at 95 °C.
	GRPR ²²¹	Peptide was coupled to CB-TE2A precursor on peptide synthesizer, followed by cleavage from resin, deprotection, and purification.	Peptide was incubated with ⁶⁴ Cu in NH ₄ OAc (0.4 M, pH 7) for 40 min at 70 °C.
	$\alpha_v\beta_6$ ²²²	CB-TE2A was pre-activated with DIC in DIEA and subsequently reacted with resin-bound peptide for 30 min at RT, followed by cleavage from the resin, deprotection, and purification.	Peptide was incubated with ⁶⁴ Cu in NH ₄ OAc (1 M, pH 7.5–8.5) for 60 min at 95 °C. Reaction quenched with EDTA.
	$\alpha_v\beta_3$ ^{99,247,248}	Peptide was reacted with CB-TE2A in the presence of DIC and HOBt in anhydrous DMF, followed by deprotection and purification.	Peptide was incubated with ⁶⁴ Cu in NH ₄ OAc (0.1 M, pH 8) for 45–120 min at 95 °C.
TETA	SSTR ^{249,250}	Lys-protected peptide was conjugated <i>in situ</i> to TETA <i>via</i> reaction with DIEA, DIC/HOBt, and HBTU in DMF (time and temperature not noted), followed by deprotection and purification.	Peptide incubated with ⁶⁴ Cu in NH ₄ OAc (0.1 M, pH 5.5) for 30 min at RT.
	SSTR ⁵⁰	Peptide was coupled to TETA(tBu) ₃ using standard Fmoc chemistry on an automated peptide synthesizer.	Peptide was incubated with ⁶⁴ Cu in NH ₄ OAc (0.1 M, pH 5.5) for 1 h at RT.
	SSTR ^{245,251–253}	Peptide was coupled to TETA(tBu) ₃ using standard Fmoc chemistry on an automated peptide synthesizer.	Peptide was incubated with ⁶⁴ Cu in NH ₄ OAc (0.1 M, pH 5.5–6.5) for 1 h at RT–37 °C.
	GC-C ²³⁹	The activated ester of TETA was formed with EDC and SNHS in sodium phosphate buffer (0.2 M, pH 8.0), followed by the addition of peptide and incubation overnight at 4 °C.	Peptide was incubated with ⁶⁴ Cu in NH ₄ OAc (0.4 M, pH 6.0) for 1 h at 80 °C. Reaction quenched with EDTA.
	$\alpha_3\beta_1$ ^{99,254}	Resin-bound peptide was combined with HBTU, DIEA, and TETA (from DMSO stock) and stirred for 4 h at RT, followed by cleavage from resin and deprotection.	Peptide was incubated with ⁶⁴ Cu in NH ₄ OAc (0.1 M, pH 5.5, 1% BSA) for 15–30 min at RT. Reaction quenched with EDTA.
NOTA	GRPR ^{255,256}	NOTA was activated for coupling <i>via</i> reaction with SNHS and EDC in MES buffer (0.1 M, pH 4.7) for 10 min at RT. Peptide (in phosphate buffer, pH 7.4) was then added to the solution, the pH was adjusted to 7.4 with 10% NaOH, and the resultant solution was stirred for 16 h at RT.	Peptide was incubated with ⁶⁴ Cu in NH ₄ OAc (0.4 M, pH 7.0) for 1 h at 70 °C. Reaction quenched with DTPA.
	GC-C ²³⁹	The activated ester of NOTA was formed with EDC and SNHS in sodium phosphate buffer (0.2 M, pH 8.0), followed by the addition of peptide and incubation overnight at 4 °C.	Peptide was incubated with ⁶⁴ Cu in NH ₄ OAc (0.4 M, pH 6.0) for 1 h at 80 °C. Reaction quenched with EDTA.
	GRPR ¹⁹⁶ $\alpha_v\beta_3$ ¹⁹⁶	Peptide was incubated with <i>p</i> -SCN-Bn-NOTA in NaHCO ₃ buffer (0.1 M, pH 9.0) for 5 h at RT.	Peptide was incubated with ⁶⁴ Cu in NaOAc (0.1 M, pH 6.5) for 15 min at 40 °C.

Table 7 (Contd.)

Chelator	Target	Conjugation ^a	Radiometallation ^{b,c}
CPTA	SSTR ²⁴⁹	Lys-protected peptide was conjugated <i>in situ</i> to CPTA <i>via</i> reaction with DIC and HOBT in DMF (time and temperature were not noted), followed by deprotection and purification.	Peptide was incubated with ⁶⁴ Cu in NH ₄ OAc (0.1 M, pH 5.5). Time and temperature were not noted.
Bis(2-mercapto-acetamide)	VPAC ^{257,258}	Protected chelator precursors were incorporated into the peptide <i>via</i> automated, solid-phase peptide synthesis using standard Fmoc/DIC/HOBT chemistry.	Peptide was incubated with ⁶⁴ Cu in glycine buffer (0.2 M, pH 9), SnCl ₂ ·2H ₂ O (0.1 M), and HCl (0.05 M) for 20–45 min at 90 °C.
BPM-TACN	GRPR ²⁵⁹	Peptide was dissolved in DMF with chelator and HBTU. Subsequently, DIPEA was added, and the resultant solution was stirred for 20 h at RT.	⁶⁴ Cu in NH ₄ OAc (0.1 M) was added to peptide in 1 : 1 MeCN : H ₂ O and incubated for 30 min at 40 °C.
DiamSar	α _v β ₃ ²⁴⁷	Peptide was reacted with DiamSar in the presence of DIC and HOBT in anhydrous DMF, followed by deprotection.	Peptide was incubated with ⁶⁴ Cu in NH ₄ OAc (0.1 M, pH 8.0) for 1 h at RT.
AmBaSar	α _v β ₃ ²⁶⁰	AmBaSar was activated for coupling <i>via</i> reaction with EDC and SNHS (1 : 1 : 0.8) in water (pH 5.5) for 30 min at 4 °C. Peptide (in water) was then added to the solution, the pH was adjusted to 8.6 with 0.1 M NaOH, and the resultant solution was stirred for 16 h at RT.	Peptide was incubated with ⁶⁴ Cu in NH ₄ OAc (0.1 M, pH 5.0) for 60 min at RT.
	α _v β ₃ ²⁶¹	AmBaSar, HATU, HOAt, and DMSO were stirred at RT for 10 min, followed by the addition of DIPEA and peptide to the solution at 0 °C and incubation for 3 h at RT.	Peptide was incubated with ⁶⁴ Cu in NH ₄ OAc (0.1 M, pH 5.0) for 30 min at RT.

^a Unless otherwise noted, peptide-chelator constructs were purified with RP-HPLC or C₁₈ cartridge prior to radiolabeling. ^b Unless otherwise noted, final radiometallated peptides were purified by RP-HPLC or C₁₈ cartridge. ^c Some protocols call for the use of gentisic acid (typically 1–5 mg mL⁻¹) to protect the biomolecule from radiolysis. ^d Purified *via* size exclusion chromatography

promising PET radiometal. However, decay properties that result in a lower image quality than ⁸⁹Zr, ⁶⁴Cu, and ⁶⁸Ga and difficulties in its production and purification have limited the development of ⁸⁶Y bioconjugates. Nevertheless, a number of ⁸⁶Y-based antibody, peptide, and oligonucleotide PET radiopharmaceuticals have been successfully synthesized and evaluated (see Table 9 for experimental details and references). For example, radiolabeled antibodies against EGFR, human epidermal growth factor 1 (HER1), Lewis Y antigen, and mindin/RG1 have been developed (Fig. 8). All of these conjugates have been synthesized *via* incubation of antibody with the CHX-A''-DTPA bifunctional chelator under basic buffer conditions, followed by purification steps to separate the bioconjugate from unreacted chelator. Radiolabeling reactions are typically performed in NH₄OAc buffer (0.1–3.0 M, pH 5–6) with incubations of 30–60 min at room temperature, followed by quenching with free chelator (*e.g.* DTPA or EDTA). The resultant completed bioconjugates are purified *via* size exclusion chromatography (*e.g.* HPLC, FPLC, or PD-10 columns) to remove any unbound ⁸⁶Y.

In addition to the antibody-based tracers, a variety peptide-based agents have been synthesized, including agents targeting MC1-R, SSTR, and GRPR. In these conjugates, CHX-A''-DTPA and DOTA have been the predominant chelators employed, with both solid-phase synthesis and bifunctional chelator conjugation routes utilized. Not surprisingly, the radiometallation conditions are dependent upon the chelator, though NaOAc and NH₄OAc buffers and pH values of 5–7 are most common. To complete the synthesis, the radiometallated peptide conjugates are almost all purified using RP-HPLC with C₁₈ or C₄ columns.

An isolated few ⁸⁶Y-labeled RNA-based conjugates have also been synthesized for mRNA targeted imaging (see Table 6 for experimental details and references). These conjugates all utilize DOTA for ⁸⁶Y chelation, and the chelator is incorporated into the oligomer *via* reaction with *p*-SCN-Bn-DOTA. Radiolabeling is accomplished *via* incubation of the chelator-RNA construct with ⁸⁶Y in NH₄OAc (0.5 M, pH 7.0) for 30–60 min at 90 °C. Unfortunately, however, only two publications on ⁸⁶Y-labeled oligonucleotide radiotracers currently exist in the literature, so more general procedures and guidelines cannot be presented here.

The construction of ⁸⁹Zr bioconjugates

Due to its long half-life, ⁸⁹Zr has been used almost exclusively in the formation of antibody bioconjugates. Yet despite this narrow range of application, a wide array of antibody-based radiopharmaceuticals have been developed, including those targeting EGFR, VEGFR, carbonic anhydrase IX (CAIX), HER2, PSMA, and B-lymphocyte antigen CD20 (CD20) (Fig. 9, see Table 10 for experimental details and references). Interestingly, one chelator, DFO, has been employed in the overwhelming majority of these bioconjugates. Two routes have dominated the reported chelator conjugations: (1) the peptide coupling of a TFP ester of an Fe^{III}(DFO) complex to the antibody of choice, followed by the removal of the Fe³⁺ cation and (2) the incubation of the antibody with a bifunctional DFO-SCN chelator. More recently, however, promising site-specific conjugation routes using maleimide- and halide-modified DFO have been reported. Regardless of the route, the resultant conjugate is typically purified *via* size exclusion

Table 8 Guide to the construction of ^{64}Cu -antibody bioconjugates

Chelator	Target	Conjugation	Radiometallation ^a	Purification
DOTA	HER2 ²⁶²	Reduced affibody (in PBS, pH 7.4) was incubated with maleimide-modified DOTA (from a stock in DMSO) for 2 h at RT, followed by purification <i>via</i> overnight dialysis.	Affibody was incubated with ^{64}Cu in NaOAc (0.1 M, pH 5.5) for 1 h at 40 °C.	Size exclusion chromatography
	HER2 ^{263,264} CEA ²⁶⁴	Activated DOTA was prepared <i>via</i> the combination of DOTA, SNHS and EDC (1 : 1 : 0.1) in water (pH 5.5) for 30 min at 4 °C. This solution was then adjusted to pH 7.3 with Na_2HPO_4 (0.2 M, pH 9.2), added to antibody (in NaH_2PO_4 , 0.1 M, pH 7.5), and incubated overnight at 4 °C. Centrifugal column filtration followed.	Antibody was incubated with ^{64}Cu in NH_4 -citrate (0.1 M, pH 5.5) for 50–60 min at 43 °C. Reaction quenched with EDTA.	Size exclusion chromatography
	$\alpha_v\beta_3$ ⁵¹ EGFR ^{53,265,266}	Activated DOTA was prepared <i>via</i> the combination of DOTA, EDC, and SNHS (10 : 5 : 4) in water (pH 5.5) for 30 min at RT. This solution was then added to antibody, the pH of the reaction mixture was adjusted to 8.5 with 0.1 M NaOH, and the solution was incubated overnight at 4 °C. Size exclusion chromatography followed for purification.	Antibody was incubated with ^{64}Cu in NaOAc (0.1 M, pH 6.5) for 1 h at 40 °C.	Size exclusion chromatography
	HER2 ²⁶⁷	Antibody was incubated with DOTA-NHS (from DMSO stock) in borate-buffered saline (0.1 M pH 8.5) for 16 h at RT, followed by size exclusion chromatography.	Antibody was incubated with ^{64}Cu in NaOAc (0.25 M, pH 6.0) for 1.5 h at 40 °C. Reaction quenched with EDTA.	Size exclusion chromatography
	CEA ²⁶⁸ TAG-72 ²⁶⁹	Antibody was first dialyzed against PBS (pH 7.2) and NaHCO_3 (0.1 M, pH 8.5). DOTA-NHS was then added to the antibody solution and incubated for 2 h at RT, followed by dialysis for purification.	Antibody was incubated with ^{64}Cu in NH_4 -citrate (0.1 M, pH 5.5) for 45 min at 43 °C.	Size exclusion chromatography
	CD22 ²⁷⁰	Antibody was incubated with DOTA-NHS in tetramethyl ammonium phosphate (0.1 M, pH 8) for 2.5 h at 37 °C, followed by centrifugal column filtration.	Antibody was incubated with ^{64}Cu in NH_4OAc (0.25 M, pH 7) for 1 h at 40 °C. Reaction quenched with EDTA.	Centrifugal column filtration
	PSMA ²⁷¹	Antibody was incubated with DOTA-NHS in Na_2HPO_4 (0.1 M, pH 7.5) for 24 h at 4 °C, followed by dialysis for purification.	Antibody was incubated with ^{64}Cu in NH_4OAc (0.25 M, final pH 5.5) for 40 min at 40 °C. Reaction quenched with DTPA.	None listed
	EGFR ²⁷²	Antibody was incubated with (tBu) ₃ DOTA-NHS in Na_2HPO_4 buffer (0.1 M, pH 7.4) for 16 h at 4 °C, followed by centrifugal column filtration.	Antibody was incubated with ^{64}Cu in NH_4 -citrate (0.1 M, pH 5.5) for 1 h at 40 °C.	Size exclusion chromatography
	L1-CAM ²⁷³	Antibody in phosphate buffer (0.1 M, pH 8) was added to DOTA-NCS variants. The pH was adjusted to 9–10 with Na_3PO_4 , and the solution was incubated for 16 h at 4 °C, followed by centrifugal column filtration.	Antibody was incubated with ^{64}Cu in NaOAc (0.1 M, pH 5.5) for 1 h at RT. Reaction quenched with EDTA.	Size exclusion chromatography
CPTA	L1-CAM ^{273,274}	Antibody was incubated with CPTA-NHS in sodium phosphate buffer (0.1 M, pH 7) for 2 h at RT, followed by centrifugal column filtration.	Antibody was incubated with ^{64}Cu in NaOAc (0.1 M, pH 5.5) for 1 h at RT. Reaction quenched with EDTA.	Size exclusion chromatography
DO3A	L1-CAM ²⁷³	Antibody in phosphate buffer (0.1 M, pH 8) was added to DO3A-Bn-NCS. The pH was adjusted to 9–10 with Na_3PO_4 , and the solution was incubated for 16 h at 4 °C, followed by centrifugal column filtration.	Antibody was incubated with ^{64}Cu in NaOAc (0.1 M, pH 5.5) for 1 h at RT. Reaction quenched with EDTA.	Size exclusion chromatography
	CEA ²⁶⁸	1. Generation of sulfhydryls on antibody <i>via</i> incubation with SATA ^b followed by $\text{NH}_2\text{OH}\cdot\text{HCl}$ 2. Purification <i>via</i> size exclusion chromatography 3. Incubation with DO3A-VS in PBS for 2 h at RT 4. Purification <i>via</i> dialysis	Antibody was incubated with ^{64}Cu in NH_4 -citrate (0.1 M, pH 5.5) for 45 min at 43 °C.	Size exclusion chromatography
	CEA ²⁶⁸	Antibody was incubated DO3A-VS in PBS (adjusted to pH 9.0 with 0.1 M NaOH) for 18 h at RT, followed by dialysis.	Antibody was incubated with ^{64}Cu in NH_4 -citrate (0.1 M, pH 5.5) for 45 min at 43 °C.	Size exclusion chromatography
TETA	CC ^{17,275}	Antibody in ammonium phosphate (0.1 M, pH 8.0) was incubated with excess Br-benzyl-TETA and fresh 2-iminothiolane in triethanolamine (50 mM) for 30 min at 37 °C, followed by centrifugal column filtration.	Antibody was incubated with ^{64}Cu in NH_4 -citrate (0.1 M, pH 5.5) for 15–30 min at RT.	Size exclusion chromatography

Table 8 (Contd.)

Chelator	Target	Conjugation	Radiometallation ^a	Purification
SarAr	GD2 ⁵⁴	Antibody was incubated with SarAr and EDC in NaOAc (0.1 M, pH 5.0) for 30 min at 37 °C, followed by size exclusion HPLC.	Antibody was incubated with ⁶⁴ Cu in NaOAc (0.1 M, pH 5.0) for 30 min at 37 °C.	None reported

^a Some protocols call for the use of gentisic acid (typically 1–5 mg mL⁻¹) to protect the biomolecule from radiolysis. ^b SATA = S-acetylthioacetate




Fig. 8 Representative reconstructed and processed maximum intensity projections of female athymic (NCr) nu/nu mice bearing (A) SHAW, (B) HT29, (C) DU145, and (D) SKOV3 tumor xenografts injected *i.v.* with 3.8–4.0 MBq of ⁸⁶Y-CHX-A''-DTPA-cetuximab. Arrows indicate tumors. The scaling is based on % maximum and minimum threshold intensity without normalization to absolute value. With kind permission from Springer Science + Business Media: T. K. Nayak, C. A. S. Regino, K. J. Wong, D. E. Milenic, K. Garmestani, K. E. Baidoo, L. P. Szajek and M. W. Brechbiel, *European Journal of Nuclear Medicine and Molecular Imaging*, **37**, 1368–1376. Fig. 3.¹⁵⁷

chromatography to remove unbound chelate and subsequently metallated with ⁸⁹Zr at pH 6.7–8.5 in buffer (HEPES and/or carbonate), with incubations of 30–120 min at room temperature. In all cases, the resultant radiolabeled bioconjugate is purified *via* size exclusion chromatography (most often GE Life Sciences PD-10 columns).

Frontiers in bioconjugate development

Both in the laboratory and in the clinic, the field of radiometallated PET bioconjugates is progressing at an exciting rate. Indeed, researchers are currently pushing back the frontiers for all of the components of the bioconjugate anatomy. To be sure, the arena with the most limited prospects is the choice of radiometal, however, efforts do exist to expand the family of PET radiometals used for bioconjugates to include new possibilities, such as ⁴⁵Ti and ⁷⁴As.^{39,40,61,68} The development of new biomolecular vectors is a particularly fertile area, with the discovery of new cancer biomarkers and advances in protein engineering fueling this growth.




Fig. 9 Temporal immunoPET images of ⁸⁹Zr-DFO-J591 recorded in (A) LNCaP tumor-bearing (PSMA-positive) and (B) PC-3 tumor-bearing (PSMA-negative) mice between 3 and 144 h after injection. Transverse and coronal planar images intersect the center of the tumors and the mean tumor-to-muscle ratios derived from volume-of-interest analysis of immunoPET images are given. Upper thresholds of immunoPET have been adjusted for visual clarity, as indicated by scale bars. Reprinted by permission of the Society of Nuclear Medicine from: J. P. Holland, V. Divilov, N. H. Bander, P. M. Smith-Jones, S. M. Larson and J. S. Lewis, *Journal of Nuclear Medicine*, 2010, **51**, 1293–1300. Fig. 4.¹²⁵

Interestingly, an increasing number of vectors are being studied, which target not specific cell-surface proteins or gene products but rather characteristics of the tumor microenvironment.⁵⁶

Yet most relevant to the discussion at hand is the forefront of research on chelation, metallation, and conjugation strategies. New chelating architectures and bifunctional chelators are being designed and synthesized at a tremendous rate, often out-stripping the pace of the development of new bioconjugates themselves.^{30–32,139} The advent of rapid, bioorthogonal, and chemoselective ‘click chemistry’ reactions represents a particularly exciting new approach to chelator conjugation.^{140–144} While the exact definition of click chemistry can vary, the most common example is the copper-catalyzed 1,3-dipolar Huisgen cycloaddition between an azide and an alkyne. The reaction is rapid, high-yielding, clean, and chemoselective and has already been extensively employed in ¹⁸F-based PET radiotracers.^{142,145,146} However, the application of click chemistry to radiometal probes has lagged behind somewhat, perhaps due to concern over Cu(I) contamination

Table 9 Guide to the construction of ^{86}Y bioconjugates

Chelator	Target	Vector	Conjugation	Radiometallation ^a	Purification
CHX-A''-DTPA	EGFR ^{157,276} HER1 ^{277,278}	Antibody	Antibody (in 0.05 M bicarbonate buffer and 0.001 M EDTA, pH 8.0) was incubated with CHX-A''-DTPA (from stock in same buffer) for 4 h at 37 °C, followed by removal of the unbound chelate by dialysis against 0.15 M NH ₄ OAc.	^{86}Y solution (in 0.1 M nitric acid) was adjusted to pH 5–6 with NH ₄ OAc buffer (5 M, pH 7.0), followed by addition of antibody (in 0.15 M NH ₄ OAc) and incubation for 30 min at RT. Reaction quenched with EDTA.	Size exclusion chromatography
	LewisY antigen ^{279–281}	Antibody and antibody fragments	Antibody was dialyzed against sodium bicarbonate buffer (0.05 M, pH 8.6) containing 0.15 M NaCl for 6 h. CHX-A''-DTPA was added to the mAb solution and incubated at RT overnight in the dark. Unbound chelate was removed by dialysis for 8 h against 20 mM NH ₄ OAc with 0.15 M NaCl (pH 6.3).	^{86}Y -acetate was prepared by mixing stock ^{86}Y solution with NH ₄ OAc (3 M, final pH 5.0), followed by addition of antibody and incubation for 30 min at RT. Reaction quenched with EDTA.	Size exclusion chromatography
	Mindin/RG1 ²⁸²	Antibody	Antibody (in 0.05 M sodium bicarbonate, 0.15 M NaCl, pH 8.5) was incubated with CHX-A''-DTPA (from DMSO stock) overnight at RT, followed by size exclusion chromatography.	^{86}Y solution (0.1 M HCl) was diluted three-fold with NH ₄ OAc (0.1 M, pH 5.6) and subsequently added to antibody for incubation at RT for 1 h. Reaction quenched with EDTA.	Size exclusion chromatography
	MC1-R ²⁸³	Peptide	Peptide was incubated with NHS ester of CHX-A''-DTPA glutarate ligand in DMF in the presence DIEA for 2 h at RT, followed by diethyl ether precipitation, deprotection, and RP-HPLC purification.	^{86}Y (in 0.1 M HCl) was incubated with peptide (in 0.5 M NH ₄ OAc, pH 5.5) at 75 °C for 30 min.	RP-HPLC
	SSTR ¹¹⁸	Peptide	Peptide was incubated with NHS ester of CHX-A''-DTPA(tBu) ₅ glutarate in DMF for 6–8 h at RT, followed by diethyl ether precipitation, deprotection, and RP-HPLC purification.	^{86}Y (in 0.1 M HCl) was incubated with peptide (in 0.5 M NH ₄ OAc, pH 5.5) at RT for 1 h.	None reported
DOTA	GRPR ^{223,284,285}	Peptide	Peptide was synthesized <i>via</i> standard Fmoc solid phase chemistry. DOTA incorporation method is unclear; however, a tributyl anhydride of DTPA was used for the acylation of prolines in similar DTPA-modified conjugates, so a similar strategy may have been used here.	^{86}Y was incubated with peptide in NH ₄ OAc (0.5 M, pH 6.5) for 30 min at 80 °C.	RP-HPLC
	MC1-R ^{219,220,286}	Peptide	Peptide was coupled to DOTA(tBu) ₃ using an automated peptide synthesizer and standard solid-phase Fmoc chemistry, followed by cleavage from the resin, deprotection, and RP-HPLC purification.	^{86}Y was incubated with peptide in NaOAc (0.1 M, pH 5.5) for 30 min at 85 °C.	RP-HPLC
	SSTR ^{287,288}	Peptide	A solution of peptide, NHS, and DCC in DMF was added to a solution of DOTA in H ₂ O, followed by incubation at RT for 24–72 h, deprotection, and RP-HPLC purification.	Peptide in NH ₄ OAc (0.15 M, pH 4.5, 0.3% BSA) was incubated with ^{86}Y (from α -hydroxyisobutyric acid stock) for 15 min at 100 °C.	RP-HPLC
	none (HSA) ¹¹⁹	Peptide Microspheres	Human serum albumin microspheres were suspended in Na ₂ B ₄ O ₇ (0.1 M, pH not noted) and incubated with <i>p</i> -SCN-Bn-DOTA for 24 h at 50 °C, followed by repeated centrifugation and washing steps for purification.	^{86}Y (in 0.04 M HCl) was added to DOTA-HSAM in NH ₄ OAc (0.5 M, pH 7) and incubated for 15 min at 90 °C at a final pH of 6.5.	Centrifugation

^a Some protocols call for the use of gentisic acid (typically 1–5 mg mL⁻¹) to protect the biomolecule from radiolysis.

Table 10 Guide to the construction of ^{89}Zr bioconjugates

Chelator	Target	Vector	Conjugation	Radiometallation ^a	Purification
DFO	EpCAM ²⁸⁹ E48 antigen ²⁸⁹	Antibody	1. Introduction of maleimide groups to mAb <i>via</i> reaction of SMCC ^b in DMF with mAb (in 0.1 M phosphate buffer, pH 8.3) for 30 min at RT 2. Reaction of DFO with SATA to form thioester 3. Incubation of SATA-DFO and freshly prepared hydroxylamine with mAb in phosphate buffer (100 mg mL ⁻¹ , pH 6.5) for 1 h at RT 4. Purification with size exclusion column	After removal of oxalic acid <i>in vacuo</i> , ^{89}Zr solution was added to a solution of mAb (0.1 M NH ₄ OAc, pH not noted) and incubated for 1 h at RT.	Size exclusion chromatography
	CD44 ^{81,290,291} Met ²⁹² EGFR ^{293,294} VEGFR ^{295,296} CD20 ²⁹⁷ HER2 ^{298,299}	Antibody	1. Synthesis of <i>N</i> -succinyl-DFO (<i>N</i> sucDFO) from DFO mesylate and succinic anhydride 2. Synthesis of Fe(III) <i>N</i> sucDFO complex from FeCl ₃ and <i>N</i> sucDFO 3. Formation of activated TFP ester of Fe(III) <i>N</i> sucDFO 4. Incubation of Fe(III) <i>N</i> sucDFO-TFP with mAb for 1 h in carbonate buffer (pH 9.5–10), followed by addition of gentisic acid, and adjustment of pH to 4–4.5 with H ₂ SO ₄ 5. Addition of EDTA (25 mg mL ⁻¹) for 30 min at pH 4–4.5 to remove Fe(III) 6. Purification with size exclusion column	Antibody solution (in water, buffer, or sterile saline) was incubated with ^{89}Zr in 0.5 M HEPES buffer for 30–60 min at RT (^{89}Zr originally in 1 M oxalic acid, adjusted to final pH 6.7–7.4 with 2 M Na ₂ CO ₃ and/or 0.5 M HEPES).	Size exclusion chromatography
	CAIX ^{300,301}	Antibody	Same as immediately above.	Same as above, but with incubation at 37 °C for 60 min.	Size exclusion chromatography
	HER2 ³⁰² PSMA ^{125,303}	Antibody	Same as immediately above.	Antibody solution (in sterile saline) was incubated with ^{89}Zr for 1–2 h at RT (^{89}Zr stock in 1 M oxalic acid adjusted to pH 7.7–8.5 with 1 M Na ₂ CO ₃).	Size exclusion chromatography
	CD44 ^{124,304} EGFR ¹²⁴ CD20 ¹²⁴	Antibody	DFO-SCN (in DMSO) was incubated with antibody in NaHCO ₃ buffer (0.1 M, pH 8.9–9.1) for 30 min at 37 °C, followed by size exclusion chromatography.	Antibody solution was incubated with ^{89}Zr in 0.5 M HEPES buffer for 60 min at RT (^{89}Zr originally in 1 M oxalic acid, adjusted to final pH 6.8–7.2 with 2 M Na ₂ CO ₃ and 0.5 M HEPES)	Size exclusion chromatography
	HER2 ³⁰⁵	Antibody	Thiol-modified antibody was incubated with DFO-Chx-Mal in buffer (50 mM Tris, 150 mM NaCl, pH 7.5) for 1 h at RT, followed by size exclusion chromatography.	Antibody solution was incubated for 1 h at RT with ^{89}Zr solution (originally in 1 M oxalic acid, adjusted to final pH 7.0–8.0, with 2 M Na ₂ CO ₃ and 0.5 M HEPES).	Size exclusion chromatography
	HER2 ³⁰⁵	Antibody	Thiol-modified antibody was incubated with DFO-BAC in buffer (0.05 M sodium borate, pH 9.0) for 5 h at RT, followed by size exclusion chromatography.	Same as immediately above	Size exclusion chromatography
	HER2 ^{304,305}	Antibody	Thiol-modified antibody was incubated with DFO-IAC in buffer (50 mM Tris, 150 mM NaCl, 0.0125 M sodium carbonate buffer pH 9) for 2 h at RT, followed by size exclusion chromatography.	Same as immediately above	Size exclusion chromatography

^a Gentisic acid (typically 1–5 mg mL⁻¹) is often included in metallation solutions to protect against radiolysis. ^b SMCC = succinimidyl 4-(*N*-maleimdomethyl) cyclohexane-1-carboxylate

from the cycloaddition catalyst. Nonetheless, a small number of ‘clickable’ bifunctional chelators and their resultant bioconjugates have begun to appear in the literature, including DOTA and CB-TE2A examples.^{147,148} Further, the development of new click reactions that do not require a copper catalyst, including [3+2]

cycloadditions between azides and strained alkynes,^{149,150} inverse electron demand Diels–Alder cycloadditions between tetrazines and strained dienophiles,^{151,152} and azaelectrocyclizations,¹⁵³ have begun to capture the interest of radiochemists and will surely soon occupy an important place in the synthesis of novel bioconjugates.

Finally, the most exciting developments in radiolabelling lie in the full automation of bioconjugate radiometallation and, perhaps ultimately, chelator conjugation as well.¹⁵⁴ Such developments will increase standardization and reproducibility while concomitantly decreasing radiation dose rates to researchers.

Conclusions

In the preceding pages, we have detailed the synthesis of radiotracers using four different radiometals, tens of biomolecular vectors, over thirty chelating scaffolds, and a myriad of different conjugation and metallation strategies. This diversity is the hallmark of an important and rapidly growing field, one that is increasingly attracting the attention of scientists from a wide variety of other specialities. Indeed, during the writing of this perspective, three new bioconjugates were published that required inclusion; between submission and publication, even more will likely appear in the literature. This influx of new interest is a boon to the molecular imaging community, bringing with it new expertise and perspectives. The rapid pace of development in this area, however, may inadvertently act as an obstacle to new researchers, simply due to the sheer number of conjugation and metallation protocols, which can vary by as much as the identity of a radiometal or by as little as a tenth of a pH unit. Therefore, we believe it is extremely important not only to encourage the development of diverse strategies for the synthesis of PET bioconjugates but also to make these experimental methods widely accessible and straightforward to the field as a whole. Our hope is that this perspective will aid in this effort.

Acknowledgements

First and foremost, the authors would like to thank all of those researchers whose work has contributed to the imaging agents discussed in these pages. Compiling this perspective has made us ever more aware of the intellectual vibrancy of this field and the scientists within it. More specifically, we would like to thank Dr Jason Holland and Dr NagaVaraKishore Pillarsetty for helpful discussions. We would also like to thank the NIH for their generous funding [NIH R01 CA138468 (JSL) and NIH F32 CA144138 (BMZ)].

References

- 1 M. Rudin and R. Weissleder, *Nat. Rev. Drug Discovery*, 2003, **2**, 123–131.
- 2 R. J. Gillies, *J. Cell. Biochem.*, 2002, **87**(S39), 231–238.
- 3 S. V. Smith, *J. Inorg. Biochem.*, 2004, **98**, 1874–1901.
- 4 P. Blower, *Dalton Trans.*, 2006, 1705–1711.
- 5 J. F. A. Mettler and M. J. Guiberteau, *Essentials of Nuclear Medicine Image (Fifth Edition)*, 2007.
- 6 J. R. Dilworth and S. J. Parrott, *Chem. Soc. Rev.*, 1998, **27**, 43–55.
- 7 I. Verel, G. W. M. Visser and G. A. van Dongen, *J. Nucl. Med.*, 2005, **46S1**, 164S–171S.
- 8 A. Mahmood and A. G. Jones, in *Handbook of Radiopharmaceuticals*, 2003, 323–362.
- 9 S. Liu and D. S. Edwards, *Chem. Rev.*, 1999, **99**, 2235–2268.
- 10 G. L. Brownell and W. H. Sweet, *Nucleonics*, 1953, **11**, 40–45.
- 11 W. H. Sweet, *N. Engl. J. Med.*, 1951, **245**, 875–878.
- 12 W. H. Sweet and G. L. Brownell, *Journal of the American Medical Association*, 1955, **157**, 1183–1188.
- 13 F. R. J. Wrenn, M. L. Good and P. Handler, *Science*, 1951, **113**, 525–527.
- 14 H. J. Bagnall, P. Benda, G. L. Brownell and W. H. Sweet, *J. Neurosurg.*, 1958, **15**, 411–426.
- 15 Y. Tang, D. Scollard, P. Chen, J. Wang, C. Holloway and R. M. Reilly, *Nucl. Med. Commun.*, 2005, **26**, 427–432.
- 16 L. C. Knight, in *Handbook of Radiopharmaceuticals*, 2003, 643–684.
- 17 C. J. Anderson, J. M. Connett, S. W. Schwarz, P. A. Rocque, L. W. Guo, G. W. Philpott, K. R. Zinn, C. F. Meares and M. J. Welch, *J. Nucl. Med.*, 1992, **33**, 1685–1691.
- 18 D. Schrama, R. A. Reisfeld and J. C. Becker, *Nat. Rev. Drug Discovery*, 2006, **5**, 147–159.
- 19 M. R. Zalutsky and J. S. Lewis, in *Handbook of Radiopharmaceuticals*, 2003, 685–714.
- 20 A. Ruangma, B. Bai, J. S. Lewis, X. Sun, M. J. Welch, R. Leahy and R. Laforest, *Nucl. Med. Biol.*, 2006, **33**, 217–226.
- 21 A. J. Beer, A. L. Grosu, J. Carlsen, A. Kolk, M. Sarbia, I. Stangier, P. Watzlowik, H. J. Wester, R. Haubner and M. Schwaiger, *Clin. Cancer Res.*, 2007, **13**, 6610–6616.
- 22 C. R. Divgi, N. Pandit-Taskar, A. A. Jungbluth, V. E. Reuter, M. Gönen, S. Ruan, C. Pierre, A. Nagel, D. A. Pryma, J. Humm, S. M. Larson, L. J. Old and P. Russo, *Lancet Oncol.*, 2007, **8**, 304–310.
- 23 T. Z. Wong, J. L. Lacy, N. A. Petry, T. C. Hawk, T. A. Sporn, M. W. Dewhirst and G. Vlahovic, *AJR, Am. J. Roentgenol.*, 2008, **190**, 427–432.
- 24 J. S. Lewis, D. W. McCarthy, T. J. McCarthy, Y. Fujibayashi and M. J. Welch, *J. Nucl. Med.*, 1999, **40**, 177–183.
- 25 A. L. Vavere and J. S. Lewis, *Dalton Trans.*, 2007, 4893–4902.
- 26 F. Dehdashti, P. W. Grigsby, J. S. Lewis, R. Laforest, B. A. Siegel and M. Welch, *J. Nucl. Med.*, 2008, **49**, 201–205.
- 27 J. S. Lewis, R. Laforest, F. Dehdashti, P. W. Grigsby, M. J. Welch and B. A. Siegel, *J. Nucl. Med.*, 2008, **49**, 1177–1182.
- 28 J. P. Holland, J. S. Lewis and F. Dehdashti, *Q. J. Nucl. Med. Mol. Imag.*, 2009, **53**, 193–200.
- 29 N. Viola-Villegas and R. P. Doyle, *Coord. Chem. Rev.*, 2009, **253**, 1906–1925.
- 30 T. J. Wadas, E. H. Wong, G. R. Weisman and C. J. Anderson, *Chem. Rev.*, 2010, **110**, 2858–2902.
- 31 R. E. Mewis and S. J. Archibald, *Coord. Chem. Rev.*, 2010, **254**, 1686–1712.
- 32 T. J. Wadas, E. H. Wong, G. R. Weisman and C. J. Anderson, *Curr. Pharm. Des.*, 2007, **13**, 3–16.
- 33 *ISI Web of Knowledge v.4.10*, Accessed October 26, 2010.
- 34 C. A. Boswell and M. W. Brechbiel, *Nucl. Med. Biol.*, 2007, **34**, 757–778.
- 35 M. P. S. Dunphy and J. S. Lewis, *J. Nucl. Med.*, 2009, **50**, 106S–121S.
- 36 S. Liu, *Chem. Soc. Rev.*, 2004, **33**, 445–461.
- 37 G. A. M. S. van Dongen, G. W. M. Visser, M. N. Lub-de Hooge, E. G. de Vries and L. R. Perk, *Oncologist*, 2007, **12**, 1379–1389.
- 38 C. J. Anderson and M. J. Welch, *Chem. Rev.*, 1999, **99**, 2219–2234.
- 39 J. S. Lewis, R. K. Singh and Michael J. Welch, *Long Lived and Unconventional PET Radionuclides*, 2009.
- 40 J. P. Holland, M. J. Williamson and J. S. Lewis, *Mol. Imaging*, 2010, **9**, 1–20.
- 41 T. K. Nayak and M. W. Brechbiel, *Bioconjugate Chem.*, 2009, **20**, 825–841.
- 42 M. Shokeen and C. J. Anderson, *Acc. Chem. Res.*, 2009, **42**, 832–841.
- 43 C. J. Anderson and R. Ferdani, *Cancer Biother. Radiopharm.*, 2009, **24**, 379–393.
- 44 A. Al-Nahhas, Z. Win, T. Szyszko, A. Singh, C. Nanni, S. Fanti and D. Rubello, *Anticancer Res.*, 2007, **27**, 4087–4094.
- 45 M. W. Brechbiel, *Q. J. Nucl. Med. Mol. Imag.*, 2008, **52**, 166–173.
- 46 D. M. Goldenberg, E. A. Rossi, R. M. Sharkey, W. J. McBride and C. H. Chang, *J. Nucl. Med.*, 2008, **49**, 158–163.
- 47 R. Schoffelen, R. M. Sharkey, D. M. Goldenberg, G. Franssen, W. J. McBride, E. A. Rossi, C. H. Chang, P. Laverman, J. A. Disselhorst, A. Eek, W. T. A. Van Der Graaf, W. J. G. Oyen and O. C. Boerman, *Mol. Cancer Ther.*, 2010, **9**, 1019–1027.
- 48 W. B. Cai and X. Y. Chen, *J. Nucl. Med.*, 2008, **49**, 113S–128S.
- 49 J. Cheon and J. H. Lee, *Acc. Chem. Res.*, 2008, **41**, 1630–1640.
- 50 M. Eiblmaier, R. Andrews, R. Laforest, B. E. Rogers and C. J. Anderson, *J. Nucl. Med.*, 2007, **48**, 1390–1396.
- 51 W. B. Cai, Y. Wu, K. Chen, Q. Z. Cao, D. A. Tice and X. Y. Chen, *Cancer Res.*, 2006, **66**, 9673–9681.

- 52 G. B. Biddlecombe, B. E. Rogers, M. de Visser, J. J. Parry, M. de Jong, J. L. Erion and J. S. Lewis, *Bioconjugate Chem.*, 2007, **18**, 724–730.
- 53 W. B. Cai, K. Chen, L. N. He, Q. H. Cao, A. Koong and X. Y. Chen, *Eur. J. Nucl. Med. Mol. Imaging*, 2007, **34**, 850–858.
- 54 S. D. Voss, S. V. Smith, N. DiBartolo, L. J. McLintos, E. M. Cyr, A. A. Bonab, J. L. J. Dearling, E. A. Carter, A. J. Fischman, S. T. Treves, S. D. Gillies, A. M. Sargeson, J. S. Huston and A. B. Packard, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 17489–17493.
- 55 X. B. Tian, R. Winter, M. R. Aruva, K. J. Zhang, C. A. Cardi, M. L. Thakur and E. Wickstrom, *Clin. Cancer Res.*, 2005, **11**, 9130S–9130S.
- 56 A. L. Vavere, G. B. Biddlecombe, W. M. Spees, J. R. Garbow, D. Wijesinghe, O. A. Andreev, D. M. Engelman, Y. K. Reshetnyak and J. S. Lewis, *Cancer Res.*, 2009, **69**, 4510–4516.
- 57 F. Dehdashti, M. A. Mintun, J. S. Lewis, J. Bradley, R. Govindan, R. Laforest, M. J. Welch and B. A. Siegel, *Eur. J. Nucl. Med. Mol. Imaging*, 2003, **30**, 844–850.
- 58 H. M. Bigott, E. Parent, L. G. Luyt, J. A. Katzenellenbogen and M. J. Welch, *Bioconjugate Chem.*, 2005, **16**, 255–264.
- 59 A. Buck, N. Nguyen, C. Burger, S. Ziegler, L. Frey, G. Weigand, W. Erhardt, R. Senekowitsch-Schmidtke, R. Pellikka, P. Blauenstein, J. T. Locher and M. Schwaiger, *Eur. J. Nucl. Med. Mol. Imaging*, 1996, **23**, 1619–1627.
- 60 N. G. Haynes, J. L. Lacy, N. Nayak, C. S. Martin, D. Dai, C. J. Mathias and M. A. Green, *J. Nucl. Med.*, 2000, **41**, 309–314.
- 61 A. L. Vavere and M. J. Welch, *J. Nucl. Med.*, 2005, **46**, 683–690.
- 62 M. Bruehlmeier, K. L. Leenders, P. Vontobel, C. Calonder, A. Antonini and A. Weindl, *J. Nucl. Med.*, 2000, **41**, 781–787.
- 63 S. C. Srivastava, K. L. Kolsky, R. C. Mease, V. Joshi, G. E. Meinken, B. Pyatt, A. P. Wolf, D. J. Schlyder, A. V. Levy and J. S. Fowler, *J. Labelled Comp. Rad.*, 1994, **35**, 389–391.
- 64 H. Wallberg, S. Ahlgren, C. Widstrom and A. Orlova, *Mol. Imaging Biol.*, 2010, **12**, 54–62.
- 65 O. Ugur, P. J. Kothari, R. D. Finn, P. Zanzonico, S. Ruan, I. Guenther, H. R. Maecke and S. M. Larson, *Nucl. Med. Biol.*, 2002, **29**, 147–157.
- 66 M. Lubberink, V. Tolmachev, C. Widstrom, A. Bruskin, H. Lundqvist and J. E. Westlin, *J. Nucl. Med.*, 2002, **43**, 1391–1397.
- 67 M. Jennewein, A. Hermanne, R. P. Mason, P. E. Thorpe and F. Rosch, *Nucl. Instrum. Methods Phys. Res., Sect. A*, 2006, **569**, 512–517.
- 68 M. Jennewein, M. A. Lewis, D. Zhao, E. Tsyganov, N. Slavine, J. He, L. Watkins, V. D. Kodibagkar, S. O'Kelly, P. Kulkarni, P. P. Antich, A. Hermanne, F. Rosch, R. P. Mason and P. E. Thorpe, *Clin. Cancer Res.*, 2008, **14**, 1377–1385.
- 69 G. J. Ehrhardt and M. J. Welch, *J. Nucl. Med.*, 1978, **19**, 925–929.
- 70 K. P. Zhernosekov, D. V. Filosofov, R. P. Baum, P. Aschoff, H. Bihl, A. A. Razbash, M. Jahn, M. Jennewein and F. Rosch, *J. Nucl. Med.*, 2007, **48**, 1741–1748.
- 71 M. Sadeghi, M. Aboudzadeh, A. Zali, M. Mirzaei and F. Bolourinovin, *Appl. Radiat. Isot.*, 2009, **67**, 7–10.
- 72 M. Sadeghi, M. Aboudzadeh, A. Zali and B. Zeinali, *Appl. Radiat. Isot.*, 2009, **67**, 1392–1396.
- 73 M. Sadeghi, A. Zali, M. Aboudzadeh, P. Sarabadani, G. Aslani and A. Majdabadi, *Appl. Radiat. Isot.*, 2009, **67**, 2029–2032.
- 74 L. S. Park, L. P. Szajek, K. J. Wong, P. S. Plascjak, K. Garmestani, S. Googins, W. C. Eckelman, J. A. Carrasquillo and C. H. Paik, *Nucl. Med. Biol.*, 2004, **31**, 297–301.
- 75 M. A. Avila-Rodriguez, J. A. Nye and R. J. Nickles, *Appl. Radiat. Isot.*, 2008, **66**, 9–13.
- 76 D. Lukic, C. Tamburella, F. Buchegger, G.-J. Beyer, J. J. Comor and Y. Seimille, *Appl. Radiat. Isot.*, 2009, **67**, 523–529.
- 77 J. Yoo, L. Tang, T. A. Perkins, D. J. Rowland, R. Laforest, J. S. Lewis and M. J. Welch, *Nucl. Med. Biol.*, 2005, **32**, 891–897.
- 78 O. T. DeJesus and R. J. Nickles, *Int. J. Radiat. Appl. Instrum., Part A*, 1990, **41**, 789–790.
- 79 J. Zweit, S. Downey and H. L. Sharma, *Int. J. Radiat. Appl. Instrum., Part A*, 1991, **42**, 199–201.
- 80 J. M. Link, K. A. Krohn, J. F. Eary, R. Kishore, T. K. Lewellen, M. W. Johnson, C. C. Badger, K. Y. Richter and W. B. Nelp, *J. Labelled Comp. Rad.*, 1986, **23**, 1297–1298.
- 81 I. Verel, G. W. M. Visser, R. Boellaard, M. Stigter-van Walsum, G. B. Snow and G. van Dongen, *J. Nucl. Med.*, 2003, **44**, 1271–1281.
- 82 W. E. Meijis, J. D. M. Herscheid, H. J. Haisma, R. Wijbrandts, F. van Langevelde, P. J. van Leuffen, R. Mooy and H. M. Pinedo, *Appl. Radiat. Isot.*, 1994, **45**, 1143–1147.
- 83 J. P. Holland, Y. C. Sheh and J. S. Lewis, *Nucl. Med. Biol.*, 2009, **36**, 729–739.
- 84 A. Obata, S. Kasamatsu, D. W. McCarthy, M. J. Welch, H. Saji, Y. Yonekura and Y. Fujibayashi, *Nucl. Med. Biol.*, 2003, **30**, 535–539.
- 85 D. W. McCarthy, R. E. Shefer, R. E. Klinkowstein, L. A. Bass, W. H. Margeneau, C. S. Cutler, C. J. Anderson and M. J. Welch, *Nucl. Med. Biol.*, 1997, **24**, 35–43.
- 86 M. A. Avila-Rodriguez, J. A. Nye and R. J. Nickles, *Appl. Radiat. Isot.*, 2007, **65**, 1115–1120.
- 87 J. Y. Kim, H. Park, J. C. Lee, K. M. Kim, K. C. Lee, H. J. Ha, T. H. Choi, G. I. An and G. J. Cheon, *Appl. Radiat. Isot.*, 2009, **67**, 1190–1194.
- 88 V. S. Le, J. Howse, M. Zaw, P. Pellegrini, A. Katsifis, I. Greguric and R. Weiner, *Appl. Radiat. Isot.*, 2009, **67**, 1324–1331.
- 89 J. Kozempel, K. Abbas, F. Simonelli, M. Zampese, U. Holzwarth, N. Gibson and L. Leseticky, *Radiochim. Acta*, 2007, **95**, 75–80.
- 90 K. Abbas, J. Kozempel, M. Bonardi, F. Groppi, A. Alfano, U. Holzwarth, F. Simonelli, H. Hofman, W. Horstmann, E. Menapace, L. Leseticky and N. Gibson, *Appl. Radiat. Isot.*, 2006, **64**, 1001–1005.
- 91 K. Hilgers, T. Stoll, Y. Skakun, H. H. Coenen and S. M. Qaim, *Appl. Radiat. Isot.*, 2003, **59**, 343–351.
- 92 L. Van So, P. Pellegrini, A. Katsifis, J. Howse and I. Greguric, *J. Radioanal. Nucl. Chem.*, 2008, **277**, 451–466.
- 93 M. Bakaj and M. Zimmer, *J. Mol. Struct.*, 1999, **508**, 59–72.
- 94 A. Pasquarello, I. Petri, P. S. Salmon, O. Parisel, R. Car, E. Toth, D. H. Powell, H. E. Fischer, L. Helm and A. E. Merbach, *Science*, 2001, **291**, 856–859.
- 95 R. Delgado, V. Felix, L. M. P. Lima and D. W. Price, *Dalton Trans.*, 2007, 2734–2745.
- 96 X. Sun, J. Kim, A. E. Martell, M. J. Welch and C. J. Anderson, *Nucl. Med. Biol.*, 2004, **31**, 1051–1059.
- 97 S. V. Smith, *Q. J. Nucl. Med. Mol. Imag.*, 2008, **52**, 193–202.
- 98 X. Sun, M. Wuest, G. R. Weisman, E. H. Wong, D. P. Reed, C. A. Boswell, R. Motekaitis, A. E. Martell, M. J. Welch and C. J. Anderson, *J. Med. Chem.*, 2002, **45**, 469–477.
- 99 T. J. Wadas and C. J. Anderson, *Nat. Protoc.*, 2006, **1**, 3062–3068.
- 100 W. P. Li, L. A. Meyer, D. A. Capretto, C. D. Sherman and C. J. Anderson, *Cancer Biother. Radiopharm.*, 2008, **23**, 158–171.
- 101 E. H. Wong, G. R. Weisman, D. C. Hill, D. P. Reed, M. E. Rogers, J. S. Condon, M. A. Fagan, J. C. Calabrese, K. C. Lam, I. A. Guzei and A. L. Rheingold, *J. Am. Chem. Soc.*, 2000, **122**, 10561–10572.
- 102 G. Bandoli, A. Dolmella, F. Tisato, M. Porchia and F. Refosco, *Coord. Chem. Rev.*, 2009, **253**, 56–77.
- 103 R. E. Weiner and M. L. Thakur, in *Handbook of Radiopharmaceuticals*, 2003, 363–399.
- 104 L. C. Francesconi, B. L. Liu, J. J. Billings, P. J. Carroll, G. Graczyk and H. F. Kung, *J. Chem. Soc., Chem. Commun.*, 1991, 94–95.
- 105 O. Jarjays, F. Mortini, A. D. d'Hardemare, C. Philouze and G. Serratrice, *Eur. J. Inorg. Chem.*, 2005, 4417–4424.
- 106 R. J. Motekaitis, A. E. Martell, S. A. Koch, J. W. Hwang, D. A. Quarless and M. J. Welch, *Inorg. Chem.*, 1998, **37**, 5902–5911.
- 107 M. J. Blend, J. J. Stastny, S. M. Swanson and M. W. Brechbiel, *Cancer Biother. Radiopharm.*, 2003, **18**, 355–363.
- 108 Y. J. Li, A. E. Martell, R. D. Hancock, J. H. Reibenspies, C. J. Anderson and M. J. Welch, *Inorg. Chem.*, 1996, **35**, 404–414.
- 109 R. Ma, R. J. Motekaitis and A. E. Martell, *Inorg. Chim. Acta*, 1994, **224**, 151–155.
- 110 A. E. Martell, R. Motekaitis, E. T. Clarke, R. Delgado, Y. Z. Sun and R. Ma, *Supramol. Chem.*, 1997, **8**, 253–253.
- 111 M. Fani, J. P. Andre and H. R. Maecke, *Contrast Media Mol. Imaging*, 2008, **3**, 53–63.
- 112 M. Eder, B. Wangler, S. Knackmuss, F. LeGall, M. Little, U. Haberkorn, W. Mier and M. Eisenhut, *Eur. J. Nucl. Med. Mol. Imaging*, 2008, **35**, 1878–1886.
- 113 E. T. Clarke and A. E. Martell, *Inorg. Chim. Acta*, 1991, **181**, 273–280.
- 114 C. J. Broan, J. P. L. Cox, A. S. Craig, R. Katak, D. Parker, A. Harrison, A. M. Randall and G. Ferguson, *J. Chem. Soc., Perkin Trans. 2*, 1991, 87–99.
- 115 D. Parker, K. Pulukkody, F. C. Smith, A. Batsanov and J. A. K. Howard, *J. Chem. Soc., Dalton Trans.*, 1994, 689–693.
- 116 K. Kumar, C. A. Chang, L. C. Francesconi, D. D. Dischino, M. F. Malley, J. Z. Gougoutas and M. F. Tweedle, *Inorg. Chem.*, 1994, **33**, 3567–3575.
- 117 S. Amin, C. Marks, L. M. Toomey, M. R. Churchill and J. R. Morrow, *Inorg. Chim. Acta*, 1996, **246**, 99–107.
- 118 T. Clifford, C. A. Boswell, G. B. Biddlecombe, J. S. Lewis and M. W. Brechbiel, *J. Med. Chem.*, 2006, **49**, 4297–4304.

- 119 E. Schiller, R. Bergmann, J. Pietzsch, B. Noll, A. Sterger, B. Johannsen, G. Wunderlich and H. J. Pietzsch, *Nucl. Med. Biol.*, 2008, **35**, 227–232.
- 120 J. Schlesinger, I. Koezle, R. Bergmann, S. Tamburini, C. Bolzati, F. Tisato, B. Noll, S. Klusmann, S. Vonhoff, F. Wuest, H. J. Pietzsch and J. Steinbach, *Bioconjugate Chem.*, 2008, **19**, 928–939.
- 121 R. L. Davidovich, V. B. Logvinova and L. V. Teplukhina, *Koordinatsionnaya Khimiya*, 1992, **18**, 580–584.
- 122 A. I. Pozhidaev, M. A. Poraikoshits and T. N. Polynova, *J. Struct. Chem.*, 1974, **15**, 548–553.
- 123 W. E. Meijs, H. J. Haisma, R. P. Klok, F. B. van Gog, E. Kievit, H. M. Pinedo and J. D. M. Herscheid, *J. Nucl. Med.*, 1997, **38**, 112–118.
- 124 L. R. Perk, M. Vosjan, G. W. M. Visser, M. Budde, P. Jurek, G. E. Kiefer and G. van Dongen, *Eur. J. Nucl. Med. Mol. Imaging*, 2010, **37**, 250–259.
- 125 J. P. Holland, V. Divilov, N. H. Bander, P. M. Smith-Jones, S. M. Larson and J. S. Lewis, *J. Nucl. Med.*, 2010, **51**, 1293–1300.
- 126 G. J. Meyer, H. R. Macke, J. Schuhmacher, W. H. Knapp and T. J. Hoffman, *Eur. J. Nucl. Med. Mol. Imaging*, 2003, **31**, 1097–1104.
- 127 I. Velikyan, A. L. Sundberg, O. Lindhe, A. U. Hoglund, O. Eriksson, E. Werner, J. Carlsson, M. Bergstrom, B. Langstrom and V. Tolmachev, *J. Nucl. Med.*, 2005, **46**, 1881–1888.
- 128 A. Dimitrakopoulou-Strauss, P. Hohenberger, U. Haberkorn, H. R. Macke, M. Eisenhut and L. G. Strauss, *J. Nucl. Med.*, 2007, **48**, 1245–1250.
- 129 Z. Liu, G. Niu, J. Shi, S. Liu, F. Wang, S. Liu and X. Chen, *Eur. J. Nucl. Med. Mol. Imaging*, 2009, **36**, 947–957.
- 130 L. Wei, X. Zhang, F. Gallazzi, Y. Miao, X. Jin, M. W. Brechbiel, H. Xu, T. Clifford, M. J. Welch, J. S. Lewis and T. P. Quinn, *Nucl. Med. Biol.*, 2009, **36**, 345–354.
- 131 K. P. Eisenwiener, M. I. M. Prata, I. Buschmann, H. W. Zhang, A. C. Santos, S. Wenger, J. C. Reubi and H. R. Macke, *Bioconjugate Chem.*, 2002, **13**, 530–541.
- 132 M. Henze, J. Schuhmacher, P. Hipp, J. Kowalski, D. W. Becker, J. Doll, H. R. Macke, M. Hofmann, J. Debus and U. Haberkorn, *J. Nucl. Med.*, 2001, **42**, 1053–1056.
- 133 A. Heppeler, S. Froidevaux, H. R. Macke, E. Jermann, M. Behe, P. Powell and M. Hennig, *Chem.–Eur. J.*, 1999, **5**, 1974–1981.
- 134 M. Hofmann, H. Maecke, A. R. Borner, E. Weckesser, P. Schoffski, M. L. Oei, J. Schuhmacher, M. Henze, A. Heppeler, G. J. Meyer and W. H. Knapp, *Eur. J. Nucl. Med. Mol. Imaging*, 2001, **28**, 1751–1757.
- 135 M. Asti, G. De Pietri, A. Fraternali, E. Grassi, R. Sghedoni, F. Floroni, F. Roesch, A. Versari and D. Salvo, *Nucl. Med. Biol.*, 2008, **35**, 721–724.
- 136 G. Lendvai, A. Monazzam, I. Velikyan, B. Eriksson, R. Josephsson, B. Langstrom, M. Bergstrom and S. Estrada, *Oligonucleotides*, 2009, **19**, 223–231.
- 137 A. Roivainen, T. Tolvanen, S. Salomaki, G. Lendvai, I. Velikyan, P. Numminen, M. Valila, H. Sipila, M. Bergstrom, P. Harkonen, H. Lonnberg and B. Langstrom, *J. Nucl. Med.*, 2004, **45**, 347–355.
- 138 J. Schlesinger, R. Bergmann, S. Klusmann and F. Wuest, *Lett. Drug Des. Discovery*, 2006, **3**, 330–335.
- 139 C. J. Anderson, M. A. Green and Y. Fujibayashi, in *Handbook of Radiopharmaceuticals*, 2003, 401–422.
- 140 T. L. Mindt, C. Muller, F. Stuker, J. F. Salazar, A. Hohn, T. Mueggler, M. Rudin and R. Schibli, *Bioconjugate Chem.*, 2009, **20**, 1940–1949.
- 141 K. Nwe and M. W. Brechbiel, *Cancer Biother. Radiopharm.*, 2009, **24**, 289–301.
- 142 M. Glaser and E. G. Robins, *J. Labelled Compd. Radiopharm.*, 2009, **52**, 407–414.
- 143 C. Waengler, R. Schirmacher, P. Bartenstein and B. Waengler, *Curr. Med. Chem.*, 2010, **17**, 1092–1116.
- 144 C. Wang, N. Wang, W. Zhou, Y. M. Shen and L. Zhang, *Progress in Chemistry*, 2010, **22**, 1591–1602.
- 145 M. Glaser, M. Solbakken, D. R. Turton, R. Pettitt, J. Barnett, J. Arukwe, H. Karlsen, A. Cuthbertson, S. K. Luthra and E. Arstad, *Amino Acids*, 2008, **37**, 717–724.
- 146 J. Marik and J. L. Sutcliffe, *Tetrahedron Lett.*, 2006, **47**, 6681–6684.
- 147 A. Y. Lebedev, J. P. Holland and J. S. Lewis, *Chem. Commun.*, 2009, **46**, 1706–1708.
- 148 S. Knor, A. Modlinger, T. Poethko, M. Schottelius, H. J. Wester and H. Kessler, *Chem.–Eur. J.*, 2007, **13**, 6082–6090.
- 149 M. E. Martin, S. G. Parameswarappa, M. S. O'Dorisio, F. C. Pigge and M. K. Schultz, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 4805–4807.
- 150 M. K. Schultz, S. G. Parameswarappa and F. C. Pigge, *Org. Lett.*, 2010, **12**, 2398–2401.
- 151 N. K. Devaraj, R. Upadhyay, J. B. Hatin, S. A. Hilderbrand and R. Weissleder, *Angew. Chem., Int. Ed.*, 2009, **48**, 7013–7016.
- 152 N. K. Devaraj, R. Weissleder and S. A. Hilderbrand, *Bioconjugate Chem.*, 2008, **19**, 2297–2299.
- 153 K. Tanaka, T. Masuyama, K. Hasegawa, T. Tahara, H. Mizuma, Y. Wada, Y. Watanabe and K. Fukase, *Angew. Chem., Int. Ed.*, 2008, **47**, 102–105.
- 154 I. Velikyan, G. J. Beyer and B. Langstrom, *Bioconjugate Chem.*, 2004, **15**, 554–560.
- 155 D. Putzer, M. Gabriel, B. Henninger, D. Kendler, C. Uprimny, G. Dobrozemsky, C. Decristoforo, R. J. Bale, W. Jaschke and I. J. Virgolini, *J. Nucl. Med.*, 2009, **50**, 1214–1221.
- 156 J. J. Parry, T. S. Kelly, R. Andrews and B. E. Rogers, *Bioconjugate Chem.*, 2007, **18**, 1110–1117.
- 157 T. K. Nayak, C. A. S. Regino, K. J. Wong, D. E. Milenic, K. Garmestani, K. E. Baidoo, L. P. Szajek and M. W. Brechbiel, *Eur. J. Nucl. Med. Mol. Imaging*, 2010, **37**, 1368–1376.
- 158 Brookhaven National Laboratory: National Nuclear Decay Center, <http://www.nndc.bnl.gov>, Accessed October 11, 2010, 2010.
- 159 M. J. Welch and C. S. Redvanly, ed., *Handbook of Radiopharmaceuticals: Radiochemistry and Applications*, Wiley, New York, 2003.
- 160 H. R. Maecke and J. P. Andre, *Ernst Schering Res. Found. Workshop*, 2007, **62**, 215–242.
- 161 G. J. Ehrhardt and M. J. Welch, *J. Nucl. Med.*, 1978, **19**, 925–929.
- 162 O. T. Dejesus and R. J. Nickles, *Int. J. Radiat. Appl. Instrum., Part A*, 1990, **41**, 789–790.
- 163 J. F. Eary, J. M. Link, R. Kishore, M. W. Johnson, C. C. Badger, K. Y. Richter, K. A. Krohn and W. B. Nelp, *J. Nucl. Med.*, 1986, **27**, 983–983.
- 164 W. E. Meijs, J. D. M. Herscheid, H. J. Haisma, R. Wijbrandts, F. Vanlangelve, P. J. Vanleuffen, R. Mooy and H. M. Pinedo, *Appl. Radiat. Isot.*, 1994, **45**, 1143–1147.
- 165 A. E. Martell and R. M. Smith, *Critical Stability Constants*, Plenum Press, New York, 1982.
- 166 A. E. Martell and R. D. Hancock, *Metal Complexes in Aqueous Solutions*, Plenum Press, New York, 1996.
- 167 A. Bevilacqua, R. I. Gelb, W. B. Hebard and L. J. Zompa, *Inorg. Chem.*, 1987, **26**, 2699–2706.
- 168 A. E. Martell, R. J. Motekaitis, E. T. Clarke, R. Delgado, Y. Z. Sun and R. Ma, *Supramol. Chem.*, 1996, **6**, 353–363.
- 169 R. Delgado and J. J. R. Dasilva, *Talanta*, 1982, **29**, 815–822.
- 170 S. Chaves, R. Delgado and J. Dasilva, *Talanta*, 1992, **39**, 249–254.
- 171 K. S. Woodin, K. J. Heroux, C. A. Boswell, E. H. Wong, G. R. Weisman, W. J. Niu, S. A. Tomellini, C. J. Anderson, L. N. Zakharov and A. L. Rheingold, *Eur. J. Inorg. Chem.*, 2005, 4829–4833.
- 172 P. K. Bharadwaj, J. A. Potenza and H. J. Schugar, *J. Am. Chem. Soc.*, 1986, **108**, 1351–1352.
- 173 P. V. Bernhardt, R. Bramley, L. M. Engelhardt, J. M. Harrowfield, D. C. R. Hockless, B. R. Korybutdaszkiewicz, E. R. Krausz, T. Morgan, A. M. Sargeson, B. W. Skelton and A. H. White, *Inorg. Chem.*, 1995, **34**, 3589–3599.
- 174 R. Delgado, M. D. Figueira and S. Quintino, *Talanta*, 1997, **45**, 451–462.
- 175 R. M. Smith and A. E. Martell, *Critical Stability Constants*, Plenum Press, New York, 1989.
- 176 R. Ma, R. J. Motekaitis and A. E. Martell, *Inorg. Chim. Acta*, 1994, **224**, 151–155.
- 177 R. J. Motekaitis, Y. Z. Sun and A. E. Martell, *Inorg. Chem.*, 1991, **30**, 1554–1556.
- 178 R. Delgado, Y. Z. Sun, R. J. Motekaitis and A. E. Martell, *Inorg. Chem.*, 1993, **32**, 3320–3326.
- 179 O. Terova, University of New Hampshire, 2008.
- 180 A. Evers, R. D. Hancock, A. E. Martell and R. J. Motekaitis, *Inorg. Chem.*, 1989, **28**, 2189–2195.
- 181 A. E. Martell and R. M. Smith, *Critical Stability Constants, Vol 1: Amino Acids*, Plenum Press, New York, 1974.
- 182 M. Koudelkova, H. Vinsova and V. Jedinakova-Krizova, *Czech. J. Phys.*, 2003, **53**, A769–A775.
- 183 M. Kodama, T. Koike, A. B. Mahatma and E. Kimura, *Inorg. Chem.*, 1991, **30**, 1270–1273.
- 184 E. Bottari and G. Anderegg, *Helv. Chim. Acta*, 1967, **50**, 2349–2355.
- 185 T. Ujula, S. Salomaki, P. Virsu, P. Lankinen, T. J. Makinen, A. Autio, G. G. Yegutkin, J. Knuuti, S. Jalkanen and A. Roivainen, *Nucl. Med. Biol.*, 2009, **36**, 631–641.

- 186 J. Schuhmacher, H. W. Zhang, J. Doll, H. R. Macke, R. Matys, H. Hauser, M. Henze, U. Haberkorn and M. Eisenhut, *J. Nucl. Med.*, 2005, **46**, 691–699.
- 187 S. Maschauer, J. Einsiedel, C. Hocke, H. Hubner, T. Kuwert, P. Gmeiner and O. Prante, *ACS Med. Chem. Lett.*, 2010, **1**, 224–228.
- 188 D. Wild, J. S. Schmitt, M. Ginj, H. R. Macke, B. F. Bernard, E. Krenning, M. de Jong, S. Wenger and J. C. Reubi, *Eur. J. Nucl. Med. Mol. Imaging*, 2003, **30**, 1338–1347.
- 189 J. de Jong, W. Bakker, E. Krenning, W. A. P. Breeman, M. E. Van Der Pluijm, B. F. Bernard, T. J. Visser, E. Jermann, M. Behe, P. Powell and H. R. Macke, *Eur. J. Nucl. Med. Mol. Imaging*, 1997, **24**, 368–371.
- 190 H. W. Zhang, J. H. Chen, C. Waldherr, K. Hinni, B. Waser, J. C. Reubi and H. R. Maecke, *Cancer Res.*, 2004, **64**, 6707–6715.
- 191 H. W. Zhang, J. Schuhmacher, B. Waser, D. Wild, M. Eisenhut, J. C. Reubi and H. R. Maecke, *Eur. J. Nucl. Med. Mol. Imaging*, 2007, **34**, 1198–1208.
- 192 S. Froidevaux, M. Calame-Christe, J. Schuhmacher, H. Tanner, R. Saffrich, M. Henze and A. N. Eberle, *J. Nucl. Med.*, 2004, **45**, 116–123.
- 193 S. Froidevaux, M. Calame-Christe, H. Tanner, L. Sumanovski and A. N. Eberle, *J. Nucl. Med.*, 2002, **43**, 1699–1706.
- 194 M. Eder, A. V. Krivoshein, M. Backer, J. M. Backer, U. Haberkorn and M. Eisenhut, *Nucl. Med. Biol.*, 2010, **37**, 405–412.
- 195 M. V. Backer, Z. Levashova, V. Patel, B. T. Jehning, K. Claffey, F. G. Blankenberg and J. M. Backer, *Nat. Med.*, 2007, **13**, 504–509.
- 196 Z. F. Liu, Y. J. Yan, S. L. Liu, F. Wang and X. Y. Chen, *Bioconjugate Chem.*, 2009, **20**, 1016–1025.
- 197 J. M. Jeong, M. K. Hong, Y. S. Chang, Y. S. Lee, Y. J. Kim, G. J. Cheon, D. S. Lee, J. K. Chung and M. C. Lee, *J. Nucl. Med.*, 2008, **49**, 830–836.
- 198 P. M. Smithjones, B. Stolz, C. Bruns, R. Albert, H. W. Reist, R. Fridrich and H. R. Macke, *J. Nucl. Med.*, 1994, **35**, 317–325.
- 199 D. J. Hnatowich, W. W. Layne and R. L. Childs, *Int. J. Appl. Radiat. Isot.*, 1982, **33**, 327–332.
- 200 S. M. Moerlein, A. Daugherty, B. E. Sobel and M. J. Welch, *J. Nucl. Med.*, 1991, **32**, 300–307.
- 201 S. J. Wagner and M. J. Welch, *J. Nucl. Med.*, 1979, **20**, 428–433.
- 202 M. Eder, S. Knackmuss, F. Le Gall, U. Reusch, V. Rybin, M. Little, U. Haberkorn, W. Mier and M. Eisenhut, *Eur. J. Nucl. Med. Mol. Imaging*, 2010, **37**, 1397–1407.
- 203 P. M. Smith-Jones, S. Vallabhajosula, S. J. Goldsmith, V. Navarro, C. J. Hunter, D. Bastidas and N. H. Bander, *Cancer Res.*, 2000, **60**, 5237–5243.
- 204 P. M. Smith-Jones, D. B. Solit, T. Akhurst, F. Alfroze, N. Rosen and S. M. Larson, *Nat. Biotechnol.*, 2004, **22**, 701–706.
- 205 P. M. Smith-Jones, D. B. Solit, F. Afroze, N. Rosen and S. M. Larson, *J. Nucl. Med.*, 2006, **47**, 793–796.
- 206 R. P. Baum, V. Prasad, D. Muller, C. Schuchardt, A. Orlova, A. Wennborg, V. Tolmachev and J. Feldwisch, *J. Nucl. Med.*, 2010, **51**, 892–897.
- 207 A. Orlova, V. Tolmachev, R. Pehrson, M. Lindborg, T. Tran, M. Sandstrom, F. Y. Nilsson, A. Wennborg, L. Abrahmsen and J. Feldwisch, *Cancer Res.*, 2007, **67**, 2178–2186.
- 208 V. Tolmachev, I. Velikyan, M. Sandstrom and A. Orlova, *Eur. J. Nucl. Med. Mol. Imaging*, 2010, **37**, 1356–1367.
- 209 F. L. Otsuka, M. J. Welch, M. R. Kilbourn, C. S. Dence, W. G. Dilley and S. A. Wells, *Int. J. Radiat. Appl. Instrum., Part A*, 1991, **18**, 813–816.
- 210 F. L. Otsuka, W. G. Cance, W. G. Dilley, R. W. Scott, J. M. Davie, S. A. Wells and M. J. Welch, *Int. J. Radiat. Appl. Instrum., Part A*, 1988, **15**, 305–311.
- 211 B. Koop, S. N. Reske and B. Neumaier, *Radiochim. Acta*, 2007, **95**, 39–42.
- 212 X. B. Tian, M. R. Aruva, K. J. Zhang, N. Shanthly, C. A. Cardi, M. L. Thakur and E. Wickstrom, *J. Nucl. Med.*, 2007, **48**, 1699–1707.
- 213 X. K. Sun, H. F. Fang, X. X. Li, R. Rossin, M. J. Welch and J. S. Taylor, *Bioconjugate Chem.*, 2005, **16**, 294–305.
- 214 G. Lendvai, I. Velikyan, M. Bergstrom, S. Estrada, D. Laryea, M. Valila, S. Salomaki and B. Langstrom, *Eur. J. Pharm. Sci.*, 2005, **26**, 26–38.
- 215 X. B. Tian, A. Chakrabarti, N. V. Amirkhanov, M. R. Aruva, K. J. Zhang, B. Mathew, C. Cardi, W. Y. Qin, E. R. Sauter, M. L. Thakur and E. Wickstrom, *Tumor Progression and Therapeutic Resistance*, 2005, **1059**, 106–144.
- 216 B. E. Rogers, H. M. Bigott, D. W. McCarthy, D. Della Manna, J. Kim, T. L. Sharp and M. J. Welch, *Bioconjugate Chem.*, 2003, **14**, 756–763.
- 217 J. J. Parry, R. Andrews and B. E. Rogers, *Breast Cancer Res. Treat.*, 2007, **101**, 175–183.
- 218 W. B. Edwards, B. Xu, W. Akers, P. P. Cheney, K. Liang, B. E. Rogers, C. J. Anderson and S. Achilefu, *Bioconjugate Chem.*, 2008, **19**, 192–200.
- 219 J. Q. Chen, Z. Cheng, N. K. Owen, T. J. Hoffman, Y. B. Miao, S. S. Jurisson and T. P. Quinn, *J. Nucl. Med.*, 2001, **42**, 1847–1855.
- 220 P. McQuade, Y. B. Miao, J. Yoo, T. P. Quinn, M. J. Welch and J. S. Lewis, *J. Med. Chem.*, 2005, **48**, 2985–2992.
- 221 J. C. Garrison, T. L. Rold, G. L. Sieckman, S. D. Figueroa, W. A. Volkert, S. S. Jurisson and T. J. Hoffman, *J. Nucl. Med.*, 2007, **48**, 1327–1337.
- 222 S. H. Hausner, D. L. Kukis, M. K. J. Gagnon, C. E. Stanecki, R. Ferdani, J. F. Marshall, C. J. Anderson and J. L. Sutcliffe, *Mol. Imaging*, 2009, **8**, 111–121.
- 223 G. B. Biddlecombe, B. E. Rogers, M. de Visser, J. J. Parry, M. de Jong, J. L. Erion and J. S. Lewis, *Bioconjugate Chem.*, 2007, **18**, 724–730.
- 224 X. Y. Chen, S. Liu, Y. P. Hou, M. Tohme, R. Park, J. R. Bading and P. S. Conti, *Mol. Imaging Biol.*, 2004, **6**, 350–359.
- 225 X. Y. Chen, Y. P. Hou, M. Tohme, R. Park, V. Khankaldyian, I. Gonzales-Gomez, J. R. Bading, W. E. Laug and P. S. Conti, *J. Nucl. Med.*, 2004, **45**, 1776–1783.
- 226 H. Y. Lee, Z. Li, K. Chen, A. R. Hsu, C. J. Xu, J. Xie, S. H. Sun and X. Y. Chen, *J. Nucl. Med.*, 2008, **49**, 1371–1379.
- 227 Y. Wu, X. Z. Zhang, Z. M. Xiong, Z. Cheng, D. R. Fisher, S. Liu, S. S. Gambhir and X. Y. Chen, *J. Nucl. Med.*, 2005, **46**, 1707–1718.
- 228 Z. B. Li, W. B. Cai, Q. Z. Cao, K. Chen, Z. H. Wu, L. N. He and X. Y. Chen, *J. Nucl. Med.*, 2007, **48**, 1162–1171.
- 229 X. Y. Chen, R. Park, Y. P. Hou, M. Tohme, A. H. Shahinian, J. R. Bading and P. S. Conti, *J. Nucl. Med.*, 2004, **45**, 1390–1397.
- 230 W. B. Cai, K. Chen, K. A. Mohamedali, Q. Z. Cao, S. S. Gambhir, M. G. Rosenblum and X. Y. Chen, *J. Nucl. Med.*, 2006, **47**, 2048–2056.
- 231 H. Wang, W. B. Cai, K. Chen, Z. B. Li, A. Kashfi, L. He and X. Y. Chen, *Eur. J. Nucl. Med. Mol. Imaging*, 2007, **34**, 2001–2010.
- 232 Z. B. Li, G. Niu, H. Wang, L. He, L. Yang, M. Ploug and X. Y. Chen, *Clin. Cancer Res.*, 2008, **14**, 4758–4766.
- 233 Q. Cao, W. Cai, G. Niu, L. He and X. Chen, *Clin. Cancer Res.*, 2008, **14**, 6137–6145.
- 234 Z. Cheng, Z. M. Xiong, M. Subbarayan, X. Y. Chen and S. S. Gambhir, *Bioconjugate Chem.*, 2007, **18**, 765–772.
- 235 L. Jiang, R. H. Kimura, Z. Miao, A. P. Silverman, G. Ren, H. G. Liu, P. Y. Li, S. S. Gambhir, J. R. Cochran and Z. Cheng, *J. Nucl. Med.*, 2010, **51**, 251–258.
- 236 R. H. Kimura, Z. Cheng, S. S. Gambhir and J. R. Cochran, *Cancer Res.*, 2009, **69**, 2435–2442.
- 237 Y. J. Liu, D. Abendschein, G. E. Woodard, R. Rossin, K. McCommis, J. Zheng, M. J. Welch and P. K. Woodard, *J. Nucl. Med.*, 2010, **51**, 85–91.
- 238 R. Rossin, S. Muro, M. J. Welch, V. R. Muzykantov and D. P. Schuster, *J. Nucl. Med.*, 2008, **49**, 103–111.
- 239 D. J. Liu, D. Overbey, L. D. Watkinson, C. J. Smith, S. Daibes-Figueroa, T. J. Hoffman, L. R. Forte, W. A. Volkert and M. F. Giblin, *Bioconjugate Chem.*, 2010, **21**, 1171–1176.
- 240 L. W. Locke, M. D. Chordia, Y. Zhang, B. Kundu, D. Kennedy, J. Landseadell, L. Xiao, K. D. Fairchild, S. S. Berr, J. Linden and D. F. Pan, *J. Nucl. Med.*, 2009, **50**, 790–797.
- 241 Z. Levashova, M. V. Backer, G. Horng, D. Felsher, J. M. Backer and F. G. Blankenberg, *Bioconjugate Chem.*, 2009, **20**, 742–749.
- 242 A. L. Vavere, G. B. Biddlecombe, W. M. Spees, J. R. Garbow, D. Wijesinghe, O. A. Andreev, D. M. Engelman, Y. K. Reshetnyak and J. S. Lewis, *Cancer Res.*, 2009, **69**, 4510–4516.
- 243 L. H. Wei, C. Butcher, Y. B. Miao, F. Gallazzi, T. P. Quinn, M. J. Welch and J. S. Lewis, *J. Nucl. Med.*, 2007, **48**, 64–72.
- 244 T. J. Wadas, M. Eiblmaier, A. Zheleznyak, C. D. Sherman, R. Ferdani, K. Liang, S. Achilefu and C. J. Anderson, *J. Nucl. Med.*, 2008, **49**, 1819–1827.
- 245 E. S. Sprague, Y. Peng, X. Sun, G. R. Weisman, E. H. Wong, S. Achilefu and C. J. Anderson, *Clin. Cancer Res.*, 2004, **10**, 8674–8682.
- 246 S. J. DeNardo, R. Liu, H. Albrecht, A. Natarajan, J. L. Sutcliffe, C. Anderson, L. Peng, R. Ferdani, S. R. Cherry and K. S. Lam, *J. Nucl. Med.*, 2009, **50**, 625–634.

- 247 L. Wei, Y. Ye, T. J. Wadas, J. S. Lewis, M. J. Welch, S. Achilefu and C. J. Anderson, *Nucl. Med. Biol.*, 2009, **36**, 277–285.
- 248 J. E. Sprague, H. Kitaura, W. Zou, Y. P. Ye, S. Achilefu, K. N. Weilbaecher, S. L. Teitelbaum and C. J. Anderson, *J. Nucl. Med.*, 2007, **48**, 311–318.
- 249 C. J. Anderson, T. S. Pajean, W. B. Edwards, E. L. C. Sherman, B. E. Rogers and M. J. Welch, *J. Nucl. Med.*, 1995, **36**, 2315–2325.
- 250 C. J. Anderson, L. A. Jones, L. A. Bass, E. L. C. Sherman, D. W. McCarthy, P. D. Cutler, M. V. Lanahan, M. E. Cristel, J. S. Lewis and S. W. Schwarz, *J. Nucl. Med.*, 1998, **39**, 1944–1951.
- 251 J. S. Lewis, M. R. Lewis, P. D. Cutler, A. Srinivasan, M. A. Schmidt, S. W. Schwarz, M. M. Morris, J. P. Miller and C. J. Anderson, *Clin. Cancer Res.*, 1999, **5**, 3608–3616.
- 252 J. S. Lewis, M. R. Lewis, A. Srinivasan, M. A. Schmidt, J. Wang and C. J. Anderson, *J. Med. Chem.*, 1999, **42**, 1341–1347.
- 253 J. S. Lewis, A. Srinivasan, M. A. Schmidt and C. J. Anderson, *Nucl. Med. Biol.*, 1999, **26**, 267–273.
- 254 W. B. Edwards, C. J. Anderson, G. B. Fields and M. J. Welch, *Bioconjugate Chem.*, 2001, **12**, 1057–1065.
- 255 A. F. Prasanphanich, P. K. Nanda, T. L. Rold, L. X. Ma, M. R. Lewis, J. C. Garrison, T. J. Hoffman, G. L. Sieckman, S. D. Figueroa and C. J. Smith, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 12462–12467.
- 256 A. F. Prasanphanich, L. Retzlaff, S. R. Lane, P. K. Nanda, G. L. Sieckman, T. L. Rold, L. X. Ma, S. D. Figueroa, S. V. Sublett, T. J. Hoffman and C. J. Smith, *Nucl. Med. Biol.*, 2009, **36**, 171–181.
- 257 M. L. Thakur, M. R. Aruva, J. Gariepy, P. Acton, S. Rattan, S. Prasad, E. Wickstrom and A. Alavi, *J. Nucl. Med.*, 2004, **45**, 1381–1389.
- 258 K. Zhang, M. R. Aruva, N. Shanthly, C. A. Cardi, S. Rattan, C. Patel, C. Kim, P. A. McCue, E. Wickstrom and M. L. Thakur, *J. Nucl. Med.*, 2008, **49**, 112–121.
- 259 G. Gasser, L. Tjioe, B. Graham, M. J. Belousoff, S. Juran, M. Walther, J. U. Kunstler, R. Bergmann, H. Stephan and L. Spiccia, *Bioconjugate Chem.*, 2008, **19**, 719–730.
- 260 H. C. Cai, J. Fissekis and P. S. Conti, *Dalton Trans.*, 2009, 5395–5400.
- 261 H. C. Cai, Z. B. Li, C. W. Huang, A. H. Shahinian, H. Wang, R. Park and P. S. Conti, *Bioconjugate Chem.*, 2010, **21**, 1417–1424.
- 262 Z. Cheng, O. P. De Jesus, D. J. Kramer, A. De, J. M. Webster, O. Gheysens, J. Levi, M. Namavari, S. Wang, J. M. Park, R. Zhang, H. Liu, B. Lee, F. A. Syud and S. S. Gambhir, *Mol. Imaging Biol.*, 2010, **12**, 316–324.
- 263 T. Olafsen, V. E. Kenanova, G. Sundaresan, A.-L. Anderson, D. Crow, P. J. Yazaki, L. Li, M. F. Press, S. S. Gambhir, L. E. Williams, J. Y. C. Wong, A. A. Raubitschek, J. E. Shively and A. M. Wu, *Cancer Res.*, 2005, **65**, 5907–5916.
- 264 M. R. Lewis, J. Y. Kao, A.-L. J. Anderson, J. E. Shively and A. Raubitschek, *Bioconjugate Chem.*, 2001, **12**, 320–324.
- 265 G. Niu, W. B. Cai, K. Chen and X. Y. Chen, *Mol. Imaging Biol.*, 2008, **10**, 99–106.
- 266 G. Niu, Z. Li, J. Xie, Q.-T. Le and X. Chen, *J. Nucl. Med.*, 2009, **50**, 1116–1123.
- 267 P. Paudyal, B. Paudyal, H. Hanaoka, N. Oriuchi, Y. Iida, H. Yoshioka, H. Tominaga, S. Watanabe, N. S. Ishioka and K. Endo, *Cancer Sci.*, 2010, **101**, 1045–1050.
- 268 L. Li, J. Bading, P. J. Yazaki, A. H. Ahuja, D. Crow, D. Colcher, L. E. Williams, J. Y. C. Wong, A. A. Raubitschek and J. E. Shively, *Bioconjugate Chem.*, 2008, **19**, 89–96.
- 269 L. Li, F. Turatti, D. Crow, J. R. Bading, A. L. Anderson, E. Poku, P. J. Yazaki, L. E. Williams, D. Tamvakis, P. Sanders, D. Leong, A. Raubitschek, P. J. Hudson, D. Colcher and J. E. Shively, *J. Nucl. Med.*, 2010, **51**, 1139–1146.
- 270 S. M. Martin, R. T. O'Donnell, D. L. Kukis, C. K. Abbey, H. McKnight, J. L. Sutcliffe and J. M. Tuscano, *Mol. Imaging Biol.*, 2008, **11**, 79–87.
- 271 U. Elsasser-Beile, G. Reischl, S. Wiehr, P. Buhler, P. Wolf, K. Alt, J. Shively, M. S. Judenhofer, H.-J. Machulla and B. J. Pichler, *J. Nucl. Med.*, 2009, **50**, 606–611.
- 272 W. P. Li, L. A. Meyer, D. A. Capretto, C. D. Sherman and C. J. Anderson, *Cancer Biother. Radiopharm.*, 2008, **23**, 158–171.
- 273 K. Zimmermann, J. Grunberg, M. Honer, S. Ametamey, P. A. Schubiger and I. Novak-Hofer, *Nucl. Med. Biol.*, 2003, **30**, 417–427.
- 274 P. Smith-Jones, R. Fridrich, T. A. Kaden, I. Novak-Hofer, K. Siebold, D. Tschudin and H. Maecke, *Bioconjugate Chem.*, 1991, **2**, 415–421.
- 275 C. J. Anderson, S. W. Schwarz, J. M. Connett, P. D. Cutler, L. W. Guo, C. J. Germain, G. W. Philpott, K. R. Zinn, D. P. Greiner, C. F. Meares and M. J. Welch, *J. Nucl. Med.*, 1995, **36**, 850–858.
- 276 D. E. Milenic, K. J. Wong, K. E. Baidoo, G. L. Ray, K. Garmestani, M. Williams and M. W. Brechbiel, *Cancer Biother. Radiopharm.*, 2008, **23**, 619–631.
- 277 T. K. Nayak, K. Garmestani, K. E. Baidoo, D. E. Milenic and M. W. Brechbiel, *J. Nucl. Med.*, 2010, **51**, 942–950.
- 278 G. L. Ray, K. E. Baidoo, K. J. Wong, M. Williams, K. Garmestani, M. W. Brechbiel and D. E. Milenic, *Br. J. Pharmacol.*, 2009, **157**, 1541–1548.
- 279 A. Lovqvist, J. L. Humm, A. Sheikh, R. D. Finn, J. Koziorowski, S. Ruan, K. S. Pentlow, A. Jungbluth, S. Welt, F. T. Lee, M. W. Brechbiel and S. M. Larson, *J. Nucl. Med.*, 2001, **42**, 1281–1287.
- 280 K. Clarke, F. T. Lee, M. W. Brechbiel, F. E. Smyth, L. J. Old and A. M. Scott, *Cancer Res.*, 2000, **60**, 4804–4811.
- 281 T. K. Nikula, M. J. Curcio, M. W. Brechbiel, O. A. Gansow, R. D. Finn and D. A. Scheinberg, *Nucl. Med. Biol.*, 1995, **22**, 387–390.
- 282 D. W. Schneider, T. Heitner, B. Alicke, D. R. Light, K. McLean, N. Satozawa, G. Parry, J. Yoo, J. S. Lewis and R. Parry, *J. Nucl. Med.*, 2009, **50**, 435–443.
- 283 L. Wei, X. Zhang, F. Gallazzi, Y. Miao, X. Jin, M. W. Brechbiel, H. Xu, T. Clifford, M. J. Welch, J. S. Lewis and T. P. Quinn, *Nucl. Med. Biol.*, 2009, **36**, 345–354.
- 284 W. A. P. Breeman, M. De Jong, B. F. Bernard, D. J. Kwekkeboom, A. Srinivasan, M. E. Van Der Pluijm, L. J. Hofland, T. J. Visser and E. P. Krenning, *Int. J. Cancer*, 1999, **83**, 657–663.
- 285 W. A. P. Breeman, M. de Jong, J. L. Erion, J. E. Bugaj, A. Srinivasan, B. F. Bernard, D. J. Kwekkeboom, T. J. Visser and E. P. Krenning, *J. Nucl. Med.*, 2002, **43**, 1650–1656.
- 286 Z. Cheng, J. Q. Chen, Y. B. Miao, N. K. Owen, T. P. Quinn and S. S. Jurisson, *J. Med. Chem.*, 2002, **45**, 3048–3056.
- 287 R. Albert, P. Smith-Jones, B. Stolz, C. Simeon, H. Knecht, C. Bruns and J. Pless, *Bioorg. Med. Chem. Lett.*, 1998, **8**, 1207–1210.
- 288 F. Rosch, H. Herzog, B. Stolz, J. Brockmann, M. Kohle, H. Muhlen-siepen, P. Marbach and H. W. Muller-Gartner, *Eur. J. Nucl. Med. Mol. Imaging*, 1999, **26**, 358–366.
- 289 W. E. Meijis, H. J. Haisma, R. P. Klok, F. B. vanGog, E. Kievit, H. M. Pinedo and J. D. M. Herscheid, *J. Nucl. Med.*, 1997, **38**, 112–118.
- 290 I. Verel, G. W. M. Visser, R. Boellaard, O. C. Boerman, J. van Eerd, G. B. Snow, A. A. Lammertsma and G. van Dongen, *J. Nucl. Med.*, 2003, **44**, 1663–1670.
- 291 P. K. E. Borjesson, Y. W. S. Jauw, R. de Bree, J. C. Roos, J. A. Castelijns, C. R. Leemans, G. van Dongen and R. Boellaard, *J. Nucl. Med.*, 2009, **50**, 1828–1836.
- 292 L. R. Perk, M. S. V. Walsum, G. W. M. Visser, R. W. Kloet, M. Vosjan, C. R. Leemans, G. Giaccone, R. Albano, P. M. Comoglio and G. van Dongen, *Eur. J. Nucl. Med. Mol. Imaging*, 2008, **35**, 1857–1867.
- 293 L. R. Perk, G. W. M. Visser, M. Vosjan, M. Stigter-van Walsum, B. M. Tijink, C. R. Leemans and G. van Dongen, *J. Nucl. Med.*, 2005, **46**, 1898–1906.
- 294 H. Aerts, L. Dubois, L. Perk, P. Vermaelen, G. van Dongen, B. G. Wouters and P. Lambin, *J. Nucl. Med.*, 2009, **50**, 123–131.
- 295 W. B. Nagengast, E. G. de Vries, G. A. Hospers, N. H. Mulder, J. R. de Jong, H. Hollema, A. H. Brouwers, G. A. van Dongen, L. R. Perk and M. N. Lub-de Hooij, *J. Nucl. Med.*, 2007, **48**, 1313–1319.
- 296 W. B. Nagengast, M. A. de Korte, T. H. O. Munnink, H. Timmer-Bosscha, W. F. den Dunnen, H. Hollema, J. R. de Jong, M. R. Jensen, C. Quad, C. Garcia-Echeverria, G. A. M. S. van Dongen, M. N. Lub-de Hooij, C. P. Schroder and E. G. E. de Vries, *J. Nucl. Med.*, 2010, **51**, 761–767.
- 297 L. R. Perk, O. J. Visser, M. S. V. Walsum, M. Vosjan, G. W. M. Visser, J. M. Zijlstra, P. C. Huijgens and G. van Dongen, *Eur. J. Nucl. Med. Mol. Imaging*, 2006, **33**, 1337–1345.
- 298 T. H. O. Munnink, M. A. de Korte, W. B. Nagengast, H. Timmer-Bosscha, C. P. Schroder, J. R. de Jong, G. van Dongen, M. R. Jensen, C. Quad, M. N. Lub-de Hooij and E. G. E. de Vries, *Eur. J. Cancer*, 2010, **46**, 678–684.
- 299 T. O. Munnink, E. Dijkers, M. L. Hooij, J. Kosterink, A. Brouwers, J. de Jong, G. van Dongen and E. de Vries, *J. Clin. Oncol.*, 2009, **27**, 1045.

- 300 A. Brouwers, I. Verel, J. Van Eerd, G. Visser, M. Steffens, E. Oosterwijk, F. Corstens, W. Oyen, G. Van Dongen and O. Boerman, *Cancer Biother. Radiopharm.*, 2004, **19**, 155–163.
- 301 B. A. W. Hoeben, J. Kaanders, G. M. Franssen, E. G. C. Troost, P. Rijken, E. Oosterwijk, G. van Dongen, W. J. G. Oyen, O. C. Boerman and J. Bussink, *J. Nucl. Med.*, 2010, **51**, 1076–1083.
- 302 J. P. Holland, E. Caldas-Lopes, V. Divilov, V. A. Longo, T. Taldone, D. Zatorska, G. Chiosis and J. S. Lewis, *Plos One*, 2010, **5**.
- 303 A. Ruggiero, J. P. Holland, J. S. Lewis and J. Grimm, *J. Nucl. Med.*, 2010, **51**, 1123–1130.
- 304 M. Vosjan, L. R. Perk, G. W. M. Visser, M. Budde, P. Jurek, G. E. Kiefer and G. van Dongen, *Nat. Protoc.*, 2010, **5**, 739–743.
- 305 J. N. Tinianow, H. S. Gill, A. Ogasawara, J. E. Flores, A. N. Vanderbilt, E. Luis, R. Vandlen, M. Darwish, J. R. Junutula, S. P. Williams and J. Marik, *Nucl. Med. Biol.*, 2010, **37**, 289–297.